On July 21, just outside of Las Cruces, New Mexico, a U.S. Customs and Border Protection (CBP) Bell UH-1N helped locate and rescue two hikers lost along the mountainous Organ Needle Trail.

And with that successful mission, the last UH-1 in operation with CBP performed its final official mission and headed for retirement. Eight days later, CBPs Air and Marine Operations (AMO), El Paso Air Branch, using that same aircraft, conducted the final flight of the UH-1N helicopter for the agency.

It went up there and searched around and we were able to coordinate the locations of search-and-rescue personnel to the people who were lost, El Paso Air Branch Director John Stonehouse told Vertical in a recent interview. They had been out there for about a day and overnight. That was the last official mission the Huey went on. So, it was nice to see it go on one more official mission.

For its farewell flight, the aircraft soared over El Paso, touring its final official home with CBP. It then came back down the taxiway at the citys international airport, where the resident fire engines saluted with arcing jets of water.

The UH-1 November model that we had really allowed us to move multiple people in and out of situations, to get into areas that were maybe higher and hotter than our smaller aircraft could get into, Stonehouse said. Were specifically talking about a law enforcement role where we have to deploy personnel or a rescue role where we are trying to recover additional personnel.

Those rescues could be officers or agents that are down, U.S. citizens that are lost or illegal migration where people have been injured or lost in specific areas that require immediate medical attention, he said.

Flying from El Paso, CBP Hueys spent most of their time operating in the rugged, remote Big Bend Sector, which spans 135,000 square miles (350,000 square kilometers) over 118 counties in Texas and Oklahoma and includes Big Bend National Park, Stonehouse said. Four of the units five UH-1Ns deployed to major hurricane relief efforts, including responding to massive flooding in Houston in the aftermath of Hurricane Harvey in 2017.

The twin-engine, medium-lift UH-1N has been in operation with AMO since Feb. 10, 2015, and was intended as a short-term asset to bridge the gap of medium-lift helicopter capabilities, as AMO initiated the UH-60 Service Life Extension Plan. With that program underway and the recent approval to standardize the medium-lift helicopter fleet to the UH-60, the UH-1N served its purpose in keeping AMOs capabilities viable.

It really has proven its value, even though it is older and its outdated in terms of what it can do, Stonehouse said. We used the UH-1 really as a stopgap capability to get to a standardized medium-lift fleet, which is in alignment with our 2030 vision and strategy.

The fleet of N-model Hueys are all former U.S. Marine Corps aircraft retired between August 2010 and September 2012 and subsequently upgraded to meet AMO requirements. Upgrades included a new communications suite, glass cockpit displays, new wire-strike kit, high-skid landing gear and tail boom and rotor modifications. The Pratt & Whitney Canada PT6T-3 engine received electrical and fuel system upgrades and installation of extended exhaust deflectors. Each aircraft received the $1.3 million upgrade to AMO standard by Rotorcraft Support Inc. of Van Nuys, California.

Since 2011, the UH-1Ns and older model Hueys have operated more than 8,000 hours, contributed to seizure of approximately 16,700 pounds of marijuana and 35 vehicles, contributed to the arrest or apprehension of 245,862 individuals, and were involved in the rescue of 152 individuals.

The five UH-1Ns will be auctioned by the General Services Administration in August. Funds generated will be returned to the AMO operating budget and immediately applied to sustainment of the UH-60 Black Hawk fleet, which will replace the UH-1N along the southern border and is in use across the continental United States and Puerto Rico.

The Hueys will be replaced with two UH-60A+ Black Hawks and one Lima-model equipped with external hoist capability. A single UH-60A is currently in operation with the second scheduled for delivery later in 2020. The UH-60L is scheduled for delivering in April 2021, Stonehouse said.

All three helicopters will come from the U.S. Army. Hoisting is extremely important along the southern U.S. borders mountainous terrain, Stonehouse said.

A lot of people dont realize, they think El Paso is flat, but weve got some big mountains up here, Stonehouse said. Plus, our [area of responsibility] extends down into Big Bend, where theres a lot of beautiful mountains. Its a gorgeous area that we have and we patrol and we get to work in every day, but it does have its environmental challenges.

Once CBP zeroes its fleet with UH-60s, the entire aviation wing of the agency will have a standardized medium-lift capability optimized for emergency response at long range, Stonehouse said.

The UH-60, the benefit it brings, we can haul twice the personnel; we can go twice the distance and about 40 percent faster than we can versus the UH-1, Stonehouse said. Of course, anytime you standardize a fleet, training costs come down, operating costs come down and the interoperability across the nation really goes up.

Continued here:
With final successful rescue, US Customs and Border Protection bids farewell to UH-1 Huey - Vertical Magazine

Recommendation and review posted by Bethany Smith

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTSThe following information should be read in conjunction with the unauditedcondensed consolidated financial statements and the notes thereto included underItem 1 of this quarterly report on Form 10-Q ("Report") and the auditedconsolidated financial statements and the related notes and Item 7 "Management'sDiscussion and Analysis of Financial Condition and Results of Operations"included in our annual report on Form 10-K for the year ended December 31, 2019(our "2019 10-K").In this Report, unless the context otherwise indicates, "we," "us" and "our"mean BWX Technologies, Inc. ("BWXT" or the "Company") and its consolidatedsubsidiaries.From time to time, our management or persons acting on our behalf makeforward-looking statements to inform existing and potential security holdersabout our Company. Forward-looking statements include those statements thatexpress a belief, expectation or intention, as well as those that are notstatements of historical fact, within the meaning of Section 27A of theSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,as amended (the "Exchange Act"). Statements and assumptions regardingexpectations and projections of specific projects, our future backlog, revenues,income and capital spending, strategic investments, acquisitions ordivestitures, return of capital activities, margin improvement initiatives orimpacts of the novel strain of coronavirus ("COVID-19") pandemic are examples offorward-looking statements. Forward-looking statements are generally accompaniedby words such as "estimate," "project," "predict," "believe," "expect,""anticipate," "plan," "seek," "goal," "could," "intend," "may," "should" orother words that convey the uncertainty of future events or outcomes. Inaddition, sometimes we will specifically describe a statement as being aforward-looking statement and refer to this cautionary statement.We have based our forward-looking statements on information currently availableto us and our current expectations, estimates and projections about ourindustries and our Company. We caution that these statements are not guaranteesof future performance and you should not rely unduly on them as they involverisks, uncertainties and assumptions that we cannot predict. In addition, wehave based many of these forward-looking statements on assumptions about futureevents that may prove to be inaccurate. For example, the extent to which theCOVID-19 outbreak impacts our business will depend on future developments thatare highly uncertain and cannot be predicted, including new information that mayemerge concerning the length and severity of the COVID-19 health crisis, and theactions to contain its impact, in addition to the potential recurrence orsubsequent waves of COVID-19 or similar diseases. While our management considersthese statements and assumptions to be reasonable, they are inherently subjectto numerous factors, including potentially the risk factors described in thesections labeled Item 1A, "Risk Factors" of our 2019 10-K, of our quarterlyreport on Form 10-Q for the quarter ended March, 31, 2020 (our "First Quarter2020 10-Q") and of this Report, most of which are difficult to predict and manyof which are beyond our control. Accordingly, our actual results may differmaterially from the future performance that we have expressed or forecast in ourforward-looking statements.We have discussed many of these factors in more detail elsewhere in this Report,including under the heading "COVID-19 Assessment" of this Item 2 "Management'sDiscussion and Analysis of Financial Condition and Results of Operations" andItem 1A, "Risk Factors", and in Item 1A "Risk Factors" in our 2019 10-K and ourFirst Quarter 2020 10-Q. These factors are not necessarily all the factors thatcould affect us. Unpredictable or unanticipated factors we have not discussed inthis Report or in our 2019 10-K and our First Quarter 2020 10-Q could also havematerial adverse effects on actual results of matters that are the subject ofour forward-looking statements. We do not intend to update or review anyforward-looking statement or our description of important factors, whether as aresult of new information, future events or otherwise, except as required byapplicable laws.GENERALWe operate in three reportable segments: Nuclear Operations Group, Nuclear PowerGroup and Nuclear Services Group. In general, we operate in capital-intensiveindustries and rely on large contracts for a substantial amount of our revenues.We are currently exploring growth strategies across our segments to expand andcomplement our existing businesses. We would expect to fund these opportunitieswith cash generated from operations or by raising additional capital throughdebt, equity or some combination thereof.Nuclear Operations GroupThe revenues of our Nuclear Operations Group segment are largely a function ofdefense spending by the U.S. Government. Through this segment, we engineer,design and manufacture precision naval nuclear components, reactors and 21-------------------------------------------------------------------------------- Table of Contentsnuclear fuel for the DOE/NNSA's Naval Nuclear Propulsion Program. In addition,we perform development and fabrication activities for missile launch tubes forU.S. Navy submarines. As a supplier of major nuclear components for certain U.S.Government programs, this segment is a significant participant in the defenseindustry.Nuclear Power GroupThrough this segment, we design and manufacture commercial nuclear steamgenerators, heat exchangers, pressure vessels, reactor components, as well asother auxiliary equipment, including containers for the storage of spent nuclearfuel and other high-level nuclear waste. This segment is a leading supplier ofnuclear fuel, fuel handling systems, tooling delivery systems, nuclear-gradematerials and precisely machined components, and related services for CANDUnuclear power plants. This segment also provides a variety of engineering andin-plant services and is a significant supplier to nuclear power utilitiesundergoing major refurbishment and plant life extension projects. Additionally,this segment is a leading global manufacturer and supplier of critical medicalradioisotopes and radiopharmaceuticals.Our Nuclear Power Group segment's overall activity primarily depends on thedemand and competitiveness of nuclear energy. A significant portion of ourNuclear Power Group segment's operations depend on the timing of maintenance andrefueling outages, the cyclical nature of capital expenditures and majorrefurbishment and life extension projects, as well as the demand for nuclearfuel and fuel handling equipment primarily in the Canadian market, which couldcause variability in our financial results.Nuclear Services GroupOur Nuclear Services Group segment provides various services to the U.S.Government. The revenues and equity in income of investees under our U.S.Government contracts are largely a function of spending of the U.S. Governmentand the performance scores we and our consortium partners earn in managing andoperating high-consequence operations at U.S. nuclear weapons sites, nationallaboratories and manufacturing complexes. With its specialized capabilities offull life-cycle management of special materials, facilities and technologies, webelieve our Nuclear Services Group segment is well-positioned to continue toparticipate in the continuing cleanup, operation and management of criticalgovernment-owned nuclear sites, laboratories and manufacturing complexesmaintained by the DOE, NASA and other federal agencies. This segment alsodevelops technology for a variety of applications, including advanced nuclearpower sources, and offers complete advanced nuclear fuel and reactor design andengineering, licensing and manufacturing services for new advanced nuclearreactors.Divestiture of U.S.-Based Commercial Nuclear Services BusinessOn May 29, 2020, our subsidiary BWXT Nuclear Energy, Inc. divested itsU.S.-based commercial nuclear services business, a component of our NuclearServices Group segment. In a cashless transaction, we exchanged net assetstotaling $18.0 million, consisting primarily of property, plant and equipmentand certain warranty obligations, for a manufacturing facility and theassociated land of approximately the same value. The acquired assets arereported as part of the Nuclear Services Group segment.Acquisition of Laker Energy Products Ltd.On January 2, 2020, our subsidiary BWXT Canada Ltd. acquired Laker EnergyProducts Ltd. ("Laker Energy Products"). Laker Energy Products is a globalsupplier of nuclear-grade materials and precisely machined components for CANDUnuclear power utilities and employs approximately 140 personnel. Laker EnergyProducts is reported as part of our Nuclear Power Group segment.Critical Accounting Policies and EstimatesFor a summary of the critical accounting policies and estimates that we use inthe preparation of our unaudited condensed consolidated financial statements,see Item 7 "Management's Discussion and Analysis of Financial Condition andResults of Operations" in our 2019 10-K. There have been no material changes toour critical accounting policies during the six months ended June 30, 2020 withthe exception of the adoption of Financial Accounting Standards Board ("FASB")Topic Intangibles - Goodwill and Other (Topic 350): Simplifying the Test forGoodwill Impairment as described in the notes to the condensed consolidatedfinancial statements in Part I of this Report. 22-------------------------------------------------------------------------------- Table of ContentsAccounting for ContractsOn certain of our performance obligations, we recognize revenue over time. Inaccordance with FASB Topic Revenue from Contracts with Customers, we arerequired to estimate the total amount of costs on these performance obligations.As of June 30, 2020, we have provided for the estimated costs to complete all ofour ongoing contracts. However, it is possible that current estimates couldchange due to unforeseen events, which could result in adjustments to overallcontract revenues and costs. A principal risk on fixed-price contracts is thatrevenue from the customer is insufficient to cover increases in our costs. It ispossible that current estimates could materially change for various reasons,including, but not limited to, fluctuations in forecasted labor productivity orsteel and other raw material prices. In some instances, we guarantee completiondates related to our projects or provide performance guarantees. Increases incosts on our fixed-price contracts could have a material adverse impact on ourconsolidated results of operations, financial condition and cash flows.Alternatively, reductions in overall contract costs at completion couldmaterially improve our consolidated results of operations, financial conditionand cash flows. During the three months ended June 30, 2020 and 2019, werecognized net changes in estimates related to contracts that recognize revenueover time, which increased operating income by approximately $11.4 million and$18.9 million, respectively. During the six months ended June 30, 2020 and 2019,we recognized net changes in estimates related to contracts that recognizerevenue over time, which increased operating income by approximately$21.0 million and $23.7 million, respectively.COVID-19 AssessmentA global outbreak of COVID-19 has occurred impacting over 200 countries,including the U.S. and Canada where we maintain our principal operations.Developments have been occurring rapidly with respect to the spread of COVID-19and its impact on human health and businesses, with new and changing governmentactions occurring on a daily basis. As a result, we have been closely monitoringthe COVID-19 pandemic and its impacts and potential impacts on our business.We have received notifications from the U.S. and Canadian governmentsdesignating BWXT as an essential business given our roles in national security,energy production and medical manufacturing. We continue to operate ourfacilities and have taken numerous precautions to mitigate exposure and protectthe health and well-being of our workforce. The COVID-19 pandemic has not causeda significant disruption to our operations or our supply chain to date.Because developments related to the spread of COVID-19 and its impacts have beenoccurring rapidly, it is difficult to predict any future impact at this time. Wemay experience material disruptions to demand for our products and services andour operations in the future as a result of, among other things, national,state, provincial or local government enforced quarantines, worker illness orabsenteeism, and travel and other restrictions. For example, we have experienceda year over year decline in revenues in our medical radioisotopes andradiopharmaceuticals business due to a decrease in demand for electivediagnostic procedures. For similar reasons, the COVID-19 pandemic may alsoadversely impact our supply chain and other manufacturers which could delay ourreceipt of essential goods and services. For example, certain services scheduledduring nuclear power plant outages during which our Nuclear Power Group segmentwould operate have been rescheduled. We have also experienced delays in thebidding and contracting process for our U.S. Government businesses due toCOVID-19 concerns. Any number of these potential risks could have a materialadverse effect on our financial condition, results of operations and cash flows.The extent to which the COVID-19 outbreak impacts our business will depend onfuture developments that are highly uncertain and cannot be predicted, includingnew information that may emerge concerning the severity of the virus and theactions to contain its impact.See Item 1A "Risk Factors" in this Report for an additional discussion of risksof the COVID-19 pandemic on our business. 23-------------------------------------------------------------------------------- Table of ContentsRESULTS OF OPERATIONS - THREE AND SIX MONTHS ENDED JUNE 30, 2020 VS. THREE ANDSIX MONTHS ENDED JUNE 30, 2019Selected financial highlights are presented in the table below: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 $ Change 2020 2019 $ Change (In thousands)REVENUES:Nuclear Operations Group $ 410,252$ 358,352$ 51,900$ 834,027$ 663,153$ 170,874Nuclear Power Group 67,983 86,639 (18,656) 155,900 171,038 (15,138)Nuclear Services Group 33,328 29,829 3,499 70,093 58,923 11,170Eliminations (7,043) (3,589) (3,454) (13,292) (5,429) (7,863) $ 504,520$ 471,231$ 33,289$ 1,046,728$ 887,685$ 159,043OPERATING INCOME:Nuclear Operations Group $ 85,972$ 75,226$ 10,746$ 176,331$ 132,851$ 43,480Nuclear Power Group 1,102 14,883 (13,781) 9,572 27,466 (17,894)Nuclear Services Group 4,122 1,490 2,632 10,522 3,061 7,461Other (5,600) (6,744) 1,144 (10,959) (12,840) 1,881 $ 85,596$ 84,855$ 741$ 185,466$ 150,538$ 34,928Unallocated Corporate (3,162) (4,320) 1,158 (4,765) (6,359) 1,594Total Operating Income $ 82,434$ 80,535$ 1,899$ 180,701$ 144,179$ 36,522Consolidated Results of OperationsThree months ended June 30, 2020 vs. 2019Consolidated revenues increased 7.1%, or $33.3 million, to $504.5 million in thethree months ended June 30, 2020 compared to $471.2 million for thecorresponding period in 2019, due to increases in revenues from our NuclearOperations Group and Nuclear Services Group segments totaling $51.9 million and$3.5 million, respectively. These increases were partially offset by a decreasein revenues in our Nuclear Power Group segment of $18.7 million.Consolidated operating income increased $1.9 million to $82.4 million in thethree months ended June 30, 2020 compared to $80.5 million for the correspondingperiod of 2019. Operating income in our Nuclear Operations Group, NuclearServices Group and Other segments increased by $10.7 million, $2.6 million, and$1.1 million, respectively. In addition, we experienced lower UnallocatedCorporate expenses of $1.2 million when compared to the corresponding period of2019. These increases were partially offset by a decrease in operating income inour Nuclear Power Group segment of $13.8 million.Six months ended June 30, 2020 vs. 2019Consolidated revenues increased 17.9%, or $159.0 million, to $1,046.7 million inthe six months ended June 30, 2020 compared to $887.7 million for thecorresponding period in 2019, due to increases in revenues from our NuclearOperations Group and Nuclear Services Group segments totaling $170.9 million and$11.2 million, respectively. These increases were partially offset by a decreasein revenues in our Nuclear Power Group segment of $15.1 million.Consolidated operating income increased $36.5 million to $180.7 million in thesix months ended June 30, 2020 compared to $144.2 million for the correspondingperiod of 2019. Operating income in our Nuclear Operations Group, NuclearServices Group and Other segments increased by $43.5 million, $7.5 million, and$1.9 million, respectively. In addition, we experienced lower UnallocatedCorporate expenses of $1.6 million when compared to the corresponding period of2019. These increases were partially offset by a decrease in operating income inour Nuclear Power Group segment of $17.9 million. 24-------------------------------------------------------------------------------- Table of ContentsNuclear Operations Group Three Months Ended Six Months Ended June 30, June 30, 2020 2019 $ Change 2020 2019 $ Change (In thousands)Revenues $ 410,252$ 358,352$ 51,900$ 834,027$ 663,153$ 170,874Operating Income $ 85,972$ 75,226$ 10,746$ 176,331$ 132,851$ 43,480% of Revenues 21.0% 21.0% 21.1% 20.0%Three months ended June 30, 2020 vs. 2019Revenues increased 14.5%, or $51.9 million, to $410.3 million in the threemonths ended June 30, 2020 compared to $358.4 million for the correspondingperiod of 2019. The increase related to the timing of the procurement of certainlong-lead materials when compared to the corresponding period of 2019 as well asadditional volume in our naval nuclear fuel and downblending operations.Operating income increased $10.7 million to $86.0 million in the three monthsended June 30, 2020 compared to $75.2 million for the corresponding period of2019. The increase was due to the operating income impact of the changes inrevenues noted above.Six months ended June 30, 2020 vs. 2019Revenues increased 25.8%, or $170.9 million, to $834.0 million in the six monthsended June 30, 2020 compared to $663.2 million for the corresponding period of2019 as we continue to expand production related to the Columbia-Class nuclearpropulsion system. The increase comprised additional volume in the manufactureof nuclear components for U.S. Government programs and the timing of theprocurement of certain long-lead materials when compared to the correspondingperiod of 2019.Operating income increased $43.5 million to $176.3 million in the six monthsended June 30, 2020 compared to $132.9 million for the corresponding period of2019. The increase was due to the operating income impact of the changes inrevenues noted above as well as favorable contract adjustments related to ournaval nuclear fuel operations.Nuclear Power Group Three Months Ended Six Months Ended June 30, June 30, 2020 2019 $ Change 2020 2019 $ Change (In thousands)Revenues $ 67,983$ 86,639$ (18,656)$ 155,900$ 171,038$ (15,138)Operating Income $ 1,102$ 14,883$ (13,781)$ 9,572$ 27,466$ (17,894)% of Revenues 1.6% 17.2% 6.1% 16.1%Three months ended June 30, 2020 vs. 2019Revenues decreased 21.5%, or $18.7 million, to $68.0 million in the three monthsended June 30, 2020 compared to $86.6 million for the corresponding period of2019. The decrease was primarily related to lower revenues in our nuclearcomponents business of $20.9 million largely attributable to decreased activityassociated with major steam generator design and supply contracts as well as adecrease in volume associated with our medical radioisotopes business. Thesedecreases were partially offset by revenues associated with the Laker EnergyProducts acquisition of $5.7 million.Operating income decreased $13.8 million to $1.1 million in the three monthsended June 30, 2020 compared to $14.9 million for the corresponding period of2019, primarily attributable to the decrease in revenues noted above as well asa decline in operating margins as a result of net favorable changes in estimatesrelated to certain long-term contracts recorded in the prior year.Six months ended June 30, 2020 vs. 2019Revenues decreased 8.9%, or $15.1 million, to $155.9 million in the six monthsended June 30, 2020 compared to $171.0 million for the corresponding period of2019. The decrease was primarily related to lower revenues in our nuclearcomponents 25-------------------------------------------------------------------------------- Table of Contentsbusiness of $11.3 million largely attributable to decreased activity associatedwith major steam generator design and supply contracts. We also experienced adecrease in revenue of $9.5 million due to lower levels of in-plant inspection,maintenance and modification services when compared to the same period in theprior year. These decreases were partially offset by revenues associated withthe Laker Energy Products acquisition.Operating income decreased $17.9 million to $9.6 million in the six months endedJune 30, 2020 compared to $27.5 million for the corresponding period of 2019,primarily attributable to the decrease in revenues noted above as well as adecline in operating margins as a result of net favorable changes in estimatesrelated to certain long-term contracts recorded in the prior year, as well ashift in our product line mix when compared to the same period in the prioryear.Nuclear Services Group Three Months Ended Six Months Ended June 30, June 30, 2020 2019 $ Change 2020 2019 $ Change (In thousands)Revenues $ 33,328$ 29,829$ 3,499$ 70,093$ 58,923$ 11,170Operating Income $ 4,122$ 1,490$ 2,632$ 10,522$ 3,061$ 7,461% of Revenues 12.4% 5.0% 15.0% 5.2%Three months ended June 30, 2020 vs. 2019Revenues increased 11.7%, or $3.5 million, to $33.3 million in the three monthsended June 30, 2020 compared to $29.8 million for the corresponding period of2019, primarily attributable to an increase in design and engineering workexecuted by our advanced technologies business.Operating income increased $2.6 million to $4.1 million in the three monthsended June 30, 2020 compared to $1.5 million for the corresponding period of2019. The increase was due to the operating income impact of the changes inrevenues noted above in addition to a decrease in selling, general andadministrative expenses related to business development activities caused by thetiming of proposal activities.Six months ended June 30, 2020 vs. 2019Revenues increased 19.0%, or $11.2 million, to $70.1 million in the six monthsended June 30, 2020 compared to $58.9 million for the corresponding period of2019. The increase was primarily attributable to design and engineering workexecuted by our advanced technologies business and an increase in the volume ofcommercial nuclear inspection and maintenance outage work in the U.S. whencompared to the same period in the prior year.Operating income increased $7.5 million to $10.5 million in the six months endedJune 30, 2020 compared to $3.1 million for the corresponding period of 2019 dueto the operating income impact of the changes in revenues noted above.Other Three Months Ended Six Months Ended June 30, June 30, 2020 2019 $ Change 2020 2019 $ Change (In thousands)

Operating Income $ (5,600)$ (6,744)$ 1,144$ (10,959)$ (12,840)$ 1,881

We do not include the value of our unconsolidated joint venture contracts inbacklog. These unconsolidated joint ventures are included in our NuclearServices Group segment.

--------------------------------------------------------------------------------

Edgar Online, source Glimpses

Original post:
BWX TECHNOLOGIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com

Recommendation and review posted by Bethany Smith

Womens health research continues to be marginalized. To address and reverse this trend requires committed, accountable leadership, inclusion of diversity of thought and critical social science issues, in addition to the more well-funded basic traditional and clinical research.

There are several areas that contribute to this marginalization, first, with respect to pregnant women. Optimizing pregnancy outcome would significantly improve world health, as babies, if born early and often thus small have higher risks of heart disease, diabetes, and asthma.

Therefore, a baby born without complications, at the right time and weight, has the potential for a healthier life. Similarly, optimizing a womans health both for a healthier pregnancy and outcome and for her long-erm health also has the potential to improve world health. A womans health is known to impact her family, including both younger and older generations, thus strategies to address womens health are essential.

Funding for womens health research is limited. The National Institutes of Health (NIH) categorizes research funding to provide consistent and transparent information on the categories of disease, conditions, and research areas.

The categorization uses sophisticated text data mining based on scientific experts to define a research category. Incredibly, 2019 was the first year that federal funding for womens health research was classified based on scientific relevance, rather than based on the percentage of female subjects included in the studies.1

The rationale for using the percentage of females enrolled in a study to count as womens health research is unclear, and unfounded, as women certainly are enrolled in studies that are not focused on womens health.In 2019, the NIH funded $4,749M in womens health research, with the largest percent (26%) by the National Cancer Institute (Figure 1).

As examples, the genetics, neurosciences, biotechnology, brain disorders, pediatrics, and aging research categories all had more NIH funding in 2019 than womens health.

To prevent transmission of the virus, all non-essential visits and encounters have been appropriately stopped, thus all ongoing clinical research has effectively ceased aside from that impacting clinical care. As I mentioned in my editorial in April, when there were only 51 studies2 - and now substantiated in 588 studies3 - pregnant and breastfeeding women are yet again excluded from research, notably from participating in COVID-19 clinical trials during this pandemic.

This is a major missed opportunity as results with therapies studied in men and nonpregnant women may not be generalizable. Furthermore, therapies are potentially not being offered to women, or if they are offered, are not being systematically studied in this population to provide needed data with which to guide therapy.

The impact of COVID-19 on womens health research highlights the long-standing inequities in including this population in research. Only in the last few decades were women required to be included in clinical research.

Yet even with this mandate, subsets of women remain excluded.

Despite mandated inclusion of women in research, womens health research remains marginalized, as are women researchers and physician-scientists. Although data suggest that women submitting NIH research project grant (RO1) applications for the first time have the same grant success rate as men4, they are half as likely to apply for those grants5, despite the fact that just as many women as men are receiving advanced degrees.

A natural history experiment using the investigator-initiated Canadian Institutes of Health Research Grant Programmes demonstrated that gender gaps in funding were due to female principal investigators being evaluated less favorably than male principal investigators - and not related to the quality of their research proposals.6

This marginalization of women researchers is rampant. As reported in numerous studies, women are less likely to be promoted, achieve tenure, or be selected for leadership roles (Supplemental figure).

Similarly, women with equal stature are less likely to be selected to participate in think tanks than men. As an example, a recent article outlining a research strategy for womens health with 17 authors included only 4 (24%) women.7

Furthermore, of the nine physician authors, only one is an ob/gyn and four are pediatricians. The themes from the think tank neglect critical areas of research, focusing on traditional sciences and emphasize genetics, overlooking the role of racial disparities and health inequities.

As noted by the 2018 NIH Gender Inequality Task Force Report, Sustainable change in representation of women, and of all individuals from underrepresented groups, requires committed, accountable leadership along with effective tools to accomplish this important goal.8 It is troubling that gender diversity in leadership positions is lacking nationally.

Using 2019 data, only 19% of department chairs (both interim and permanent) are held by women. Extrapolating the trend lines suggests another 50 years are needed to attain parity of department chairs and medical school deans by gender (Figure 2).

This diversity is not due to a lack of qualified women, as since 2002, women have earned the majority of all doctorates9 and in 2019, women comprise the majority of enrolled US medical students.10

Underrepresentation creates a culture that perpetuates inequalities. For our patients, for ourselves, for our families, we must correct this course. This is not easy, and will require a change of culture led by a committed, accountable, proactive leadership.

Equally important will be the inclusion of diversity and broadening of the research agenda to include critical social science issues, health disparities, and social determinants of health.

One ray of hope to address these pressing issues is the formation of the Womxns Health Collaborative, a group determined to identify and initiate actionable steps.

If you are interested in participating, I encourage you to contact Dr. Michal Elovitz at womxnshealth@gmail.com.

__

__

See more here:
Addressing inequalities in women's health research - Contemporary Obgyn

Recommendation and review posted by Bethany Smith

Chris McGregor, right, who farmed with his father, David, near Antrim, has opended a new veterinary practice in Scotland, and is pictured with his business partner, Ross Wilson.

David McGregor, who farms 130 cows on robots near Antrim was one of the first farmers to take on the new system of genetic improvement.

He explained: We had two reasons for starting the RMS Optimise Program. Firstly, we knew from experience, that Genus ABS had the expertise to provide the service and the bull stud to back up the genetics. Secondly, my son, who had been heavily involved with the fertility program in the herd, was starting up Tinto Farm Vets, a new veterinary practice in Scotland, so his focus was moving to that business venture. We started to investigate the options. Gareth Bell, breeding advisor with Genus ABS suggested RMS Optimise. We studied the system in depth and decided that it fitted in with our plans for the dairy enterprise.

David outlined his experience with the RMS Optimise program: The Technician, Michael Scott, calls at the same time everyday to detect cows on heat and ensures they are mated with the appropriate genetics for our overall aims for the herd and the cows individual genetic requirements. In addition he looks after all the paperwork, providing detailed fertility reports which enable us to ensure that our feeding program, compiled by David from FarmGate Nutrition, complements our overall aims for the herd.

David emphasised; A successful dairy enterprise needs a team effort, with input from breeding adviser, nutritionist, vet etc. and Genus ABS takes account of all aspects when advising on our breeding program.

The net result has been a decrease of nearly 50 days off our calving interval which now has a projected calving interval of 383 days. Milk yield has increased from 34 litres per day up to 39 litres at present. Our pregnancy rate has improved greatly - we are now hitting 25%.

Simon Logan, explains: Pregnancy rate is the measure of how fast your herd is becoming pregnant and is your conception rate multiplied by your submission rate. Basically, the UK average is around 13%. David and Chris have almost doubled this in their first year of RMS Optimise which is a fantastic achievement.

David added: We have more milk in the tank and less cows culled due to infertility and so we have been able to sell surplus heifers and generated more income. We have also generated quite a few British blue calves not to mention a lot of valuable Sexcel pregnancies.

Simon Logan emphasised that the new RMS Optimise program has many more additional benefits. He explained: Farmers who utilise this program can create 67% of pregnancies with easy calving British Blue sires which should produce a cash crop of high value calves. All of the benefits will, in turn, mean increased milk production and pregnancy rates, a decreased calving interval, minimise the number of low value Holstein male calves and provide detailed management reports.

He added: In our first year of launching the Optimise service we had 19 customers all coming on for various reasons. It has been exciting to be a part of something that has really helped a lot of our customers. We have had 13 years of providing the RMS service in Northern Ireland and it now includes almost 40,000 cows improving the fertility and management of these herds. RMS Optimise further enhances this service and, in turn, the financial performance of the farm. We have had a lot of interest in the service and are aiming to accommodate more customers, although space will be limited so please contact your local Genus ABS representative for a free on farm consultation.

Read the original here:
One year on from the launch of RMS Optimise from Genus ABS - Farming Life

Recommendation and review posted by Bethany Smith

The advent of gene expression assays has provided predictive insight into chemotherapy benefit that can be combined with prognostic information yielded by gene expression profiling to better target patients with breast cancer who are at higher clinical risk for the use of adjuvant chemotherapy, according to Joseph A. Sparano, MD.

The notion of precision medicine in breast cancer is not a new concept; it dates back to the 1970s when we began using ER and PR protein expression initially by ligand-binding assay and then by immunohistochemistry to identify patients who would benefit from adjuvant endocrine therapy, said Sparano, a professor of medicine and womens health at Albert Einstein College of Medicine, in a presentation during the 19th AnnualInternational Congress on the Future of Breast Cancer West, a virtual program by Physician Education Resource (PER).1

We then entered the second generation using gene amplification for HER2/neu via FISH testing to identify women who could benefit from adjuvant trastuzumab (Herceptin), an anti-HER2based therapy, added Sparano. Fifteen years into the third generation [we use] gene expression profiles to guide the use of adjuvant chemotherapy and endocrine therapy. We're currently pretty far into the fourth generation of assays in terms of mutational profiling, which can identify individuals who could benefit from targeted therapies.

In his presentation, Sparano, who is also an associate chairman in the Department of Oncology at Montefiore Medical Center, provided insight into advances made with gene expression profiles, the clinical utility of available assays, as well as future directions in this area.

Gene expression profiles first emerged in the breast cancer paradigm about 15 years ago based on unsupervised analyses, which indicated that breast cancer was a heterogenous disease, that there were distinct subtypes, and that prognosis could vary by subtype, according to Sparano. The unsupervised work resulted in the PAM50 assay (Prosigna), which can be used to identify the distinct breast cancer subtypes that exist.

The next generation of gene expression assays were based on supervised analyses, which evaluated genes associated with a better or worse prognosis. This research led to the development of various prognostic assays, which included the 21-Gene recurrence score assay (Oncotype DX) and the 70-Gene signature test (MammaPrint), among others.

One important point is that theres a lack of concordance in the prognostic classification provided by these assays, said Sparano.

Prospective Validation

The first trial to show that a gene expression assay could provide independent prognostic information was the B14 trial, which included archival samples from a total of 668 patients with estrogen receptor (ER)positive, node-negative breast cancer who had received treatment with tamoxifen for 5 years.

Fifty-one percent of patients fell into the low-risk group, which was defined as a recurrence score (RS) of less than 18, 22% of patients were in the intermediate-risk group (RS of 18-30), and 27% were in the high-risk group (RS of 31 or greater). The 10-year risk of distant recurrence was 7%, 14%, and 31%, respectively, for each of these groups.2

Further data revealed a statistically significant association for RS that was independent of age and tumor size, said Sparano. As such, RS was not a surrogate marker for these other factors; it provided independent prognostic information.

Results from another study, referred to as B20, went on to demonstrate prediction of benefit with these assays.3 A total of 651 patients with ER-positive, node-negative breast cancer were randomized to receive tamoxifen or tamoxifen plus chemotherapy. For the entire cohort you see approximately a 4% improvement in distant relapse-free survival for patients who received chemotherapy, noted Sparano. However, there was a very large benefit for patients who had a RS of 31 or higher; the absolute benefit was in the range of about 25% in the group with the highest RS, suggesting that one can identify, using this assay, a subpopulation of patients who are deriving all of the benefit from chemotherapy.

The prospective TAILORx trial included women with hormone receptorpositive, HER2-negative, and axillary node-negative breast cancer and they were randomized to treatment based on their RS.

Of the 10,273 women enrolled on the trial, 1629 who had a low RS of 0 to 10, were assigned to receive endocrine therapy alone (arm A). Women with a high RS of 26 to 100 were assigned to endocrine therapy plus chemotherapy (arm D). Those in the midrange who had a RS of 11 to 25 were randomized to receive either endocrine therapy plus chemotherapy in the standard arm (arm C), versus endocrine therapy alone in the experimental arm (arm B).

The study had a noninferiority design with invasive disease-free survival (iDFS) as the primary end point, and full information is expected after 835 iDFS events were reported.

We modified the mid-range group for several reasons. The TAILORx population excluded HER2-positive disease and we know that the 21-gene assay includes a HER2 module that drives the RS up and is associated with a higher score, but we know that most HER2-positive tumors have a higher RS, explained Sparano.5 As such, if you use the assay in a HER2-negative population, youll have a different RS distribution.

Additionally, the RS assay is used selectively in practice in situations where there is therapeutic equipoise, which is typically intermediate-grade tumors that are 1 cm to 2 cm; this results in more tumors having a score in the mid-range group, according to Sparano. The trial really needed to be designed to address that group, he said.

Moreover, the RS range was adjusted to preserve prediction in the highest-risk group and minimize the potential for undertreatment in the low-risk group, Sparano added.

Initial data from the low-risk group showed that at 5 years, the rate of freedom from recurrence of breast cancer at a distant site was 99.3% (95% CI, 98.7%-99.6%).4 This information was subsequently integrated into the American Joint Committee on Cancers Cancer Staging Manual, noted Sparano.

After a median of 7.5 years, results from the intent-to-treat population (arms B and C) were released and showed that the primary end point for iDFS was met (HR, 1.08; 95% CI, 0.94-1.24; P = .26), demonstrating noninferiority of endocrine therapy compared with the standard.6 Endocrine therapy alone was also found to be noninferior to chemoendocrine therapy with regard to freedom of recurrence of breast cancer at a distant site (HR, 1.10; 95% CI, 0.85-1.41; P = .48).

Investigators then examined whether any patients with a mid-range score were still deriving benefit from the chemotherapy. No benefit was observed with regard to increasing tumor size or grade, but statistically significant chemotherapy treatment interactions were observed between age, RS, and chemotherapy benefit. Patients who had a higher RS and a higher clinical risk within this younger group seemed to derive benefit, explained Sparano.

At 9 years, in those with a RS of 16-20, a 1.6% absolute benefit from chemotherapy was observed versus a 6.5% absolute benefit in those with RS ranging from 21 to 25, added Sparano.

An exploratory analysis looking at the impact of age and menopausal status on chemotherapy benefit in patients with a RS ranging from 16 to 25 showed that there was no benefit in older women with an increasing score. However, curves began to separate for younger women with a RS of less than 25, noted Sparano.

When examining absolute differences in 9-year distant recurrence rates by chemotherapy use in women 50 years or younger with RS of 16 to 25 stratified by RS and clinical risk, investigators noted that the estimated absolute benefit of chemotherapy in women with a RS of 16 to 20 who were not stratified by clinical risk was +1.6%. The estimated absolute chemotherapy benefit stratified by clinical risk was -0.2% in those with low clinical risk (n = 671) and a RS between 16 and 20 and +6.5% in those with high clinical risk (n = 215).7

When looking at the impact of age on chemotherapy benefit, investigators observed that women who were closer to menopause, aged 46 to 50 years, experienced the greatest benefit. Interestingly, younger women really had no benefit, suggesting that some of the effect that was seen with chemotherapy in these younger patients who had higher RS might have been due to a castration effect, explained Sparano.

At 9 years, a 3% distant recurrence with endocrine therapy alone was observed in patients with an RS of 0 to 10 (arm A). An overall 5% distant recurrence rate was reported in those with an RS between 11 and 25 (arms B and C). Between arms B and C, a less than 1% difference was observed for all end points. In those with a RS between 26 and 100 (Arm D), a 13% distant recurrence was observed, despite chemotherapy plus endocrine treatment.

MINDACT

The MINDACT trial included 6,693 patients who were assigned to a clinical risk or a genomic risk. Patients who had discordance in their clinical and genomic risks were randomized to receive either no chemotherapy or chemotherapy.8 The primary end point of the trial was distant metastasis-free survival at 5 years for those with high clinical risk and low genomic risk without chemotherapy.

No effect with chemotherapy was observed in older women, but there was a 5% benefit from chemotherapy in younger women, which is very similar to what we saw in TAILORx, said Sparano.

The phase 3 Plan B trial used the Oncotype DX Recurrence Score to define a genomically low-risk subset of patients with clinically high-risk pN0-1 early breast cancer for adjuvant treatment with endocrine therapy alone. A total of 3198 patients were enrolled on the trial and chemotherapy was omitted in 86.1% of eligible patients with a RS of 11 or less.

At a median follow-up of 5 years, DFS in the patients treated with endocrine therapy alone who had a RS of 11 of less was 94% versus 94% in those with an RS between 12 and 25 and 84% in those with an RS of greater than 25 (P < .001). In patients who received chemotherapy, the 5-year overall survival was 99% versus 97% versus 93%, respectively (P < .001).

This provided a limited amount of level 1 evidence supporting the use of the Oncotype assay in patients with low-volume disease, noted Sparano.

Future Directions

With all of the data yielded thus far, it is clear that gene expression assays provide prognostic information, that the 21-gene assay offers predictive information, and that the 70-gene assay provides prognostic information, according to Sparano.

Its important to remember that these assays are not interchangeable, and theres a lack of concordance in risk classification which needs to be considered when deciding which assay to use and what to do with the information yielded, concluded Sparano. Future plans involve integration of the clinical and gene expression profile information to recalibrate existing tools in an effort to provide more refined information regarding prognosis as well as an estimation of chemotherapy benefit.

Read more:
Sparano Shares Progress Made in the Molecular Guided Management of Breast Cancer - OncLive

Recommendation and review posted by Bethany Smith

If youve noticed patchy or thinning spots on your scalp or a surplus of hair strands on your hairbrush or in the shower, you're not alone. More than half of all women will experience noticeable hair loss, according to the Cleveland Clinic. In order to put a stop to shedding, though, you have to figure out the root of the problem. Hair loss is not a diagnosis, says Yolanda Lenzy, M.D., M.P.H.,board-certified dermatologist and licensed cosmetologist in Chicopee, Massachusetts. Hair loss is a symptom. Once you get a specific diagnosis, then you can know the causes associated with that diagnosis.

For starters, know that the term alopecia refers to all kinds of hair loss. There are two main types of alopecia, and then a variety of forms of hair loss within those two categories. In cases of non-scarring or temporary hair loss, the missing hair will eventually grow back. With scarring or permanent hair loss, permanent damage is done to the hair follicles so they wont grow back. With scarring hair loss, the goal is not for it to grow back, but to stop the progression, says Dr. Lenzy. Below, are seven different kinds of alopecia knowing which one youre suffering from will help determine the proper treatment.

When people talk about male or female pattern hair loss typically a receding hair line in men or thinning at the crown in women thats androgenetic alopecia. Its the most common form of hair loss among all people. In fact, research shows that more than 50% of women will develop androgenetic alopecia by the age of 80. It can come from either side of the family in men or women, skip a generation, and start earlier in the next generation that the one before it, says dermatologist Carolyn Goh, M.D., Health Sciences Assistant Clinical Professor at the David Geffen School of Medicine and Director of the Hair and Scalp Disorder Clinic at UCLA. However, some people have pattern hair loss without a family history of it. While some women start showing signs of androgenetic alopecia in their teenage years, others wont experience it until their 50s or 60s. When nearing menopause, the decrease of estrogen means you have unopposed testosterone, says Dr. Lenzy. That elevated testosterone can convert to a hormone called dihydrotestosterone (DHT), which contributes to the thinning of the hair follicles the follicles actually get smaller in this particular form of hair loss.

Telogen effluvium is just a fancy name for excessive hair shedding an annoyance that many people will experience at some point in their life. A common cause is stress, usually meaning major life stressors or physical stressors like surgery, medication (including over the counter ones and supplements), weight loss, or a death in the family, to name a few, says Dr. Goh. It usually starts three to six months after a stressor and then lasts for three to six months. Hypothyroidism and iron deficiency can also trigger telogen effluvium. The beautiful thing about it is 70% of your hair strands are still in the anagen or growing phase, adds Dr. Lenzy. Because the hair follicles work in a cycle, you wont go bald.

This type of hair loss affects about 2% of people and usually appears as round smooth circles anywhere on the head without any redness, itching, or pain. Alopecia areata is thought to be caused by an autoimmune process, says Dr. Lenzy. The bodys immune system makes some mistakes and produces T cells that attack hair follicles.

Thinning and bald patches at the temples or where hair is frequently pulled tight can indicate traction alopecia. This very common form of hair loss is caused by haircare and hairstyle practices practices which place excessive tension or weight on the follicles like braids, ponytails, hair extensions, or locs.

Central centrifugal cicatricial alopecia tends to start on the top of the head with breakage and thinning, and often with some tenderness of the scalp, says Dr. Goh. It gradually spreads outward and can cause permanent hair loss. CCCA is especially common among Black women. Some recent studies have found that about 25% of people with this form of hair loss have a genetic mutation in one of the proteins thats responsible for the formation of the hair follicle, says Dr. Lenzy. On top of that, she notes that the same haircare practices that create tension and cause traction alopecia also contribute to CCCA.

Lichen planopilaris can result in patchy spots of hair loss as well as redness, itching, burning, or pain in the scalp. Its a form of alopecia thats found more commonly among caucasian women. LPP is thought to be autoimmune-related and but research is still being done to figure out the exact cause. Theres some research that shows individuals with this form of hair loss have decreased activity of a very essential enzyme called PPAR-gamma, says Dr. Lenzy. PPAR-gamma is responsible for how our scalps metabolize lipids on the scalp so when individuals dont have that active, they can develop LPP. One particular form of LPP called frontal fibrosing alopecia (FFA) is becoming increasingly common in postmenopausal women, according to Dr. Goh. In FFA, the hairline recedes gradually from the front and sides and sometimes the back of the scalp, she says. Eyebrows are often lost and sometimes eyelashes and other body hair.

Lupus of the scalp is another form of scarring alopecia thats autoimmune, says Dr. Lenzy. Its common, especially in women of color. It shows up as red, scaly, thick lesions that dont usually hurt or itch.

Holger ScheibeGetty Images

Trichorrhexis nodosa is the official name for hair breakage. It takes place mid-shaft while hair loss occurs at the scalp. For instance, if you see little hairs on the floor of different lengths, thats a sign of breakage, says Dr. Lenzy. But with shedding, the hair is coming out from the root so you will see long strands the entire length of your hair. Hair color, excessive heat during styling, and chemical straighteners can all dry out hair strands, making them more likely to break. If your haircare practices are the culprit, youll see breakage throughout your hair. However, isolated breakage in one spot can be a sign of alopecia areata or CCCA.

The cause of your particular form of hair loss will point you toward the right treatment. For stress-related telogen effluvium, time is usually the best solution as hair should grow back six to nine months after the excessive shedding occurs. However, if your telogen effluvium is caused by an underlying health issue such as a thyroid problem or low iron levels, your hair should grow back after you address the underlying problem.

Topical minoxidil (Rogaine) is the only FDA-approved treatment for hair loss in women, says Dr. Goh. Its technically approved for androgenetic alopecia, but its used for many types of hair loss, and its available over the counter. A common reason people dont try minoxidil is because they have heard you have to keep using it forever, says Dr. Goh. While it is true that minoxidil only works while you use it, it is also true of all treatments for hair loss as long as the underlying hair loss is chronic. It can become a routine like brushing your teeth. Finasteride (Propecia) is FDA-approved for male pattern androgenetic alopecia and is quite effective, especially when combined with minoxidil. Its often prescribed off-label for women, but can cause birth defects so its usually used in women after child-bearing age, notes Dr. Goh. Spironolactone is another medication often used for women with female pattern hair loss that can cause birth defects so women are advised to use proper contraception while taking it.

If you have one of the forms of scarring alopecia that is inflammatory, such as CCCA, we often use antibiotics to decrease inflammation around the hair follicle, says Dr. Lenzy. Topical or injection cortisones can also be helpful in reducing inflammation in CCCA as well as in alopecia areata. There are a lot of new treatments on the horizon that are currently being studied in clinical trials for extensive forms of alopecia areata, adds Dr. Lenzy. Some of the treatments that are coming down the pike, we currently use off-label even though theyre not yet approved. In general, many of the treatments for hair loss are experimental because theres just not a lot of FDA-approved treatments. But those of us who specialize in hair loss, we have a lot of effective therapies that we use.

Be cautious about vitamins, supplements, and shampoos that claim to help hair loss, advises Dr. Goh. None of these have been studied thoroughly and they often cost a lot of money. Theres also little regulation of these products by the FDA so theres no guarantee that they are both safe and effective.

In particular, you should steer clear of supplements that contain large amounts of biotin as there is little proof that it is helpful in people who have normal biotin levels which is most people. About two years ago, the FDA issued a warning that mega doses of biotin can alter many of your lab results, including your thyroid function tasks and cardiac enzymes, says Dr. Lenzy. People think just because something is natural or a vitamin then it cant be harmful, but that couldnt be farther from the truth. If you happen to take a multivitamin that contains a smaller amount of biotin, stop taking it two to three days before having any bloodwork conducted to ensure that your results are accurate.

While other purported natural treatments like castor oil might be benign, Dr. Lenzy doesnt recommend them because they may not be effective. If you have a form of scarring alopecia, the most important thing is for you to get an early diagnosis, she says. This is permanent hair loss so if you spend six months to a year trying castor oil, youre losing precious follicles that whole time that you wont be able to get back. She says the best thing you can do is get a proper diagnosis from a doctor: These are actual medical conditions just like high blood pressure or diabetes. I see so many people suffering and trying different things and if they had only come in sooner, their result would be so much better.

Yulia ReznikovGetty Images

Everyones shedding pattern is a little different so theres no standard amount of hair loss that warrants a call to your dermatologist. Some people shed very little and some people shed a lot at baseline, says Dr. Goh. We say losing 100 to 200 hairs per day can be normal and people usually shed more on a shampoo day than a non-shampoo day. She points out that many people stop washing their hair when they see it falling out, but you should continue to wash your hair every 1 to 2 days to keep your scalp healthy to promote hair growth. Keep in mind that a receding hair line and thinning hair can both occur without visible shedding. I would recommend seeing a doctor if there are clearly visible bald spots, itching or burning of the scalp, or the hair loss has been going on for longer than six months, says Dr. Goh. Also, if there is a significant family history of hair loss, it may be a good idea to come in sooner than later.

The key is to find the right doctor. Seek out a board-certified dermatologist who specializes in hair loss and will be aware of newer treatments currently being studied. Keep track of any other symptoms like fatigue or joint pain, says Dr. Goh, as those pieces of the puzzle may help your physician identify underlying conditions. Along those same lines, dont be afraid to get a second opinion. Ive had people whove seen me after three or four opinions and they were told nothing could be done because they had a form a scarring alopecia, says Dr. Lenzy. But theres always something that can be done. If you do nothing, in five years you may have 25% or 50% of the hair you have now, but with treatment you may be able to slow the hair loss process down substantially. The goal in some conditions is not to get the hair to grow back, emphasizes Dr. Lenzy. The goal is stabilization and help is available.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

See the article here:
Hair Loss in Women Guide: Causes and Treatment for Thinning Hair and Alopecia - GoodHousekeeping.com

Recommendation and review posted by Bethany Smith

SAN DIEGO: Being HempTM, the makers of THC-free CBD products formulated doctors to specifically address women's unique health, wellness and beauty needs, launched a line of products designed to deliver pure, powerful results for female consumers - an anti-aging skin care system, five condition-specific tinctures, and the first-ever apple cider vinegar gummies featuring high-absorption Nano CBD.

There is a big difference between marketing existing CBD products to women and creating physician-formulated products that meet women's specific needs, said Liz Gagnon, Director of Communications for Being Hemp. As we looked at the landscape of CBD products, we found that women are looking for CBD products that speak directly to their concerns and that they can trust to work as advertised. We're confident that Being Hemp products will deliver the pure, powerful results that women expect and deserve.

Product Launch Summary

Being Hemp Apple Cider Vinegar Nano CBD Gummies The first of their kind, these watermelon-flavored apple cider vinegar (ACV) gummies support overall health and well-being, offering 350mg of ACV and 25mg of Nano CBD per gummie - more than twice the CBD of most other gummies. ACV is commonly used as a natural appetite suppressant and is known for various healthful properties, including antimicrobial and antioxidant effects. Evidence suggests it may offer additional health benefits, such as aiding weight loss, reducing cholesterol, lowering blood sugar levels, and improving the symptoms of diabetes.

The Being Hemp Anti-Aging Skin Care System This doctor-formulated, three-product system utilizes the most advanced dermatological science plus proven natural ingredients to achieve timeless results for women of every age and skin type. All three clean label products are hypoallergenic, sulfate-free, and synthetic fragrance-free, and include superior-absorbing Nano CBD to restore cellular balance and reduce puffiness, as well as Hyaluronic Acid to hydrate and reduce lines and wrinkles.

Beautiful Age-Defying Serum, a light, silky cream to leave skin looking youthful and healthy with real and lasting benefits that start at the cellular level to fuel regeneration and visibly defy the signs of aging. The serum features Collagen to dramatically improve skin elasticity; Saw Palmetto to trigger enzyme production; and, Vitamins A and B support to cell rejuvenation.Beautiful Day Creme, a superior moisturizer that protects skin from the damage caused by sun exposure and airborne free radicals without leaving an oily residue or clogging pores. Formulated to give make-up incredible staying power, it features Vitamin E and Rose Hip Oil to improve elasticity and minimize the signs of aging, as well as Titanium Oxide to naturally protects against harmful UVA and UVB rays.Beautiful Night Creme, a skin-pampering formulation to reverse daytime damage. Made with a relaxing lavender scent and a hint of vanilla, it features Vitamin A to fuel cell regeneration and Rosehip Oil to improve elasticity and minimize the signs of aging.All three products are packaged in an innovative, airless pump jar that protects product purity and integrity while providing 1-finger dispensing convenience.

Being Hemp Tinctures These five, condition-specific, gluten-free formulations deliver 50 mg of Nano CBD per 1ml serving. Each includes Omega 3-6-9, Vitamins C and D, Zinc and Theanine, a Green Tea extract.

Restful, a sleep formula with Melatonin and Lavender;Immune, an immune booster with Turmeric and Elderberry;Serene, a stress and anxiety formula with Bacopa and Limonene;Centered, a PMS/mood formula with Ashwagandha and Evening Primrose; andHarmony, a hormone balance formula with St. John's Wort and Black Cohosh Root.

All Being Hemp products are crafted in GMP-certified facilities to ensure consistency, safety, quality control and reliability for every batch. The company uses only the most reputable third-party testing labs to verify all product ingredients and potencies for every batch. The Certificate of Analysis (COA) for any Being Hemp product can be viewed online.

More here:
Being Hemp Launches Proprietary Nano CBD Products Specifically Formulated to Target Womens Health, Wellness and Beauty Needs-NK#137011 - New Kerala

Recommendation and review posted by Bethany Smith

3 August 2020

Thirty-three genes associated with male infertility have been identified through a 'genomics-first' approach to understanding the condition.

Researchers from the King Faisal Specialist Hospital and Research Centre in Saudi Arabia used exomesequencing, a method for sequencingall the protein-coding regions of genesin a genome, to establish a genetic basis for infertility in male patients. It is hoped that a more complete understanding of the molecularbiology behind male infertility, alongside greater application of genomic medicine, will lead to improvements in treatment and diagnosis.

'Male factors account for nearly half of infertility caseswith nearly seven percent of the male population estimated to suffer from infertility' the authors reported in the journal Genetics in Medicine. 'However, current estimates of the contribution of genetics to male infertility (15 percent) suffer from the lack of comprehensive genomic analysis in large cohorts.'

From a non-selected sample of 285 infertile male patients, 69 (24.2 percent) were suspected of displaying a monogenic form of male infertility, meaning that it was caused by a defect in a single gene. Over 400 genes have already been associated with male infertility in mouse models, suggesting that that the monogenic contribution in humans has been significantly underestimated.

The current standard method for diagnosing the cause of male infertility involves screening for chromosomal aberrations, such as Y-chromosome micro-deletions too small to spot by karyotype. However, this technique has a low diagnostic yield, and aberrations were only identified in 30 (10.5 percent) of the patients included in the study.

Of the 285 patients included in the study, 237 presented with non-obstructive azoospermia a failure to make sperm resulting in no sperm in the ejaculate. The remaining 48 patients displayed severe oligospermia, characterised by a sperm count lower than one million sperm per millilitre. An identical number of fertile men were recruited to the study as controls.

'The 33 candidate genes we identified in this study represents by far the largest number of male infertility genes discovered by a single study,' Dr Fowzan Alkuraya, the principal clinical scientist behind the study toldGenomeWeb. 'There are only around 40 genes linked to non-obstructive azoospermia in humans. Thus, our study nearly doubles the genes linked to this phenotype.'

These candidate genes were also selected and verified based on known biological roles in male germ celldevelopment, as well as from compatible mouse models. Three of these genes were deemed as having 'strong evidence' of a connection to male infertility in humans, based on evidence from mouse models, as well as displaying independent variants in multiple unrelated patients.

The scientists are hopeful that these results will encourage further research dissecting the molecular basis of male infertility, as well as the development of future therapies and methods to improve its diagnosis and management.

See original here:
Known genes associated with male infertility doubled - BioNews

Recommendation and review posted by Bethany Smith

Different stories: People with 16p11.2 copy number variations who dont have autism can have autism-like traits, such as language impairment.

MoMo Productions / Getty Images

Mutations to the chromosomal region 16p11.2 affect people in different ways, often leading to some combination of autism, intellectual disability and language difficulties. Two new studies help to account for this diversity of traits1,2.

Up to 25 percent of people with a duplication or deletion of DNA, or copy number variation (CNV), in 16p11.2 have autism; the rest often have at least one autism trait, according to previous research. People with 16p11.2 CNVs also have varying levels of cognitive and language abilities. And as with other genetic influences on autism, 16p11.2 CNVs seem to affect boys more often, or at least more severely, than girls.

Were looking across different parts of the phenotype and trying to understand how all of these pieces connect together, says Caitlin Hudac, assistant professor of psychology at the University of Alabama in Tuscaloosa.

One of the new studies, led by Hudac, explored how various traits relate to additional genetic and environmental factors in 96 people with 16p11.2 deletions and 77 with duplications.

The researchers tallied each participants experiences of perinatal and prenatal events associated with autism, such as having a low birth weight or a mother who had preeclampsia.

They also sequenced the participants DNA to identify other mutations that could have contributed to the traits, which they assessed using standardized tests. They then developed a statistical model that, based on five factors number of prenatal events, number of perinatal events, other CNVs, other gene mutations, and sex accounted for 9 to 20 percent of the variability in individual traits.

For example, deletion carriers who had experienced the most perinatal events tended to have a low verbal intelligence quotient (IQ) and poor adaptive behavior, or the ability to carry out daily tasks such as eating or getting dressed, the researchers found. And duplication and deletion carriers who had experienced a higher number of perinatal events or had additional CNVs tended to have a low nonverbal IQ.

The researchers also saw a female protective effect: Compared with their male counterparts, female duplication carriers were less likely to have difficulties with social interaction, and female deletion carriers were less likely to have restricted and repetitive behaviors.

The work was published in June in Autism Research.

The results are in line with the idea that multiple factors work together to contribute to variation in autism traits, says Santhosh Girirajan, associate professor of genomics at Pennsylvania State University in University Park, who was not involved in either study. The 16p11.2 CNVs on their own are not deterministic, he says.

The second study, conducted by a different team, similarly shows how variable the effects of 16p11.2 deletions and duplications are by focusing on a single outcome: language impairment.

Many past studies have highlighted language impairments mostly in deletion carriers, mainly by giving language testing in highly structured settings, says lead researcher So Hyun Sophy Kim, assistant professor of psychology in clinical psychology at Weill Cornell Medical College in New York City.

Kim and her colleagues used multiple complementary testing methods, including one that allowed them to evaluate language abilities in a naturalistic setting. They tested 110 children and young adults with a 16p11.2 deletion and 58 with a duplication.

Deletion and duplication carriers both seemed to show difficulties using their language in a social way, Kim says. In particular, the children had the most trouble with pragmatic language, or being able to have back-and-forth conversation with someone, sharing interests and offering information about their own experiences.

The difficulties existed even in children with no autism diagnosis or cognitive deficit, suggesting that this language impairment is characteristic of the CNVs. The results were published in June in the American Journal of Medical Genetics.

Learning more about the diversity of traits across people with 16p11.2 CNVs could help identify the different needs and the different abilities of people with these genetic variants, says Nicola Grissom, assistant professor of psychology at the University of Minnesota in Minneapolis, who was not involved in either study.

Researchers from both studies suggest that the most effective way to influence positive outcomes for children with 16p11.2 CNVs is early identification and intervention.

For language impairments, that means starting therapy before age 5, when an explosion of language development is thought to occur, Kim says. Comprehensive language assessments can help ensure that happens.

The ultimate goal, Hudac says, is to be able to understand how everything works together in order to develop successful treatments. Her team is incorporating additional factors into their statistical model, such as the genetic and environmental backgrounds of a persons parents, in an attempt to further explain the variability in 16p11.2 CNV-associated traits.

More here:
Studies unravel diversity of traits tied to chromosome 16 mutations - Spectrum

Recommendation and review posted by Bethany Smith

This report additionally covers the effect of COVID-19 on the worldwide market. The pandemic brought about by Coronavirus (COVID-19) has influenced each part of life all inclusive, including the business segment. This has brought along a several changes in economic situations.

The Male Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

It incorporates Male Breast Cancer market evolution study, involving the current scenario, growth rate (CAGR), and SWOT analysis. Important the study on Male Breast Cancer market takes a closer look at the top market performers and monitors the strategies that have enabled them to occupy a strong foothold in the market. Apart from this, the research brings to light real-time data about opportunities that will completely transform the trajectory of the business environment in the coming years to 2025. Some of the key players in the global Male Breast Cancer market is cccc

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ http://marketresearchbazaar.com/requestSample/58345

According to 99Strategy, the Global Male Breast Cancer Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during the 2021-2026. The report analyses the global Male Breast Cancer market, the market size and growth, as well as the major market participants.

The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels.The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.

Key Regions

Asia Pacific

North America

Europe

South America

Middle East & Africa

Key Companies

Pfizer

Roche

GlaxoSmithKline

Sanofi

Novartis

Bayer

Bristol-Myers Squibb

Eli Lilly

AstraZeneca

Teva Pharmaceutical

Sun Pharmaceutical

BioNumerik Pharmaceuticals

Seattle Genetics

Accord Healthcare

Key Product Type

Medication

Chemotherapy

Others

Market by Application

Hospitals

Clinics

Others

Main Aspects covered in the Report

Overview of the Male Breast Cancer market including production, consumption, status & forecast and market growth

2016-2020 historical data and 2021-2026 market forecast

Geographical analysis including major countries

Overview the product type market including development

Overview the end-user market including development

Impact of Coronavirus on the Industry

Enquiry Before Buying: http://marketresearchbazaar.com/enquiry/58345

Major Point of TOC:

Chapter One: Male Breast Cancer Market Overview

Chapter Two: Male Breast Cancer Market Segment Analysis by Player

Chapter Three: Male Breast Cancer Market Segment Analysis by Type

Chapter Four: Male Breast Cancer Market Segment Analysis by Application

Chapter Five: Male Breast Cancer Market Segment Analysis by Sales Channel

Chapter Six: Male Breast Cancer Market Segment Analysis by Region

Chapter Seven: Profile of Leading Male Breast Cancer Players

Chapter Eight: Upstream and Downstream Analysis of Male Breast Cancer

Chapter Nine: Development Trend of Male Breast Cancer (2020-2029)

Chapter Ten: Appendix

Read Full Report: http://marketresearchbazaar.com/requestSample//detail/58345

If you have any special requirements, please let us know and we will offer you the report as you want.

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

UK: +442070973908

US: +13156360953

India: +919548234540

Email:[emailprotected]

Website:http://marketresearchbazaar.com/

Blog:http://marketresearchbazaar.com/blogs

Follows to Twitter :https://twitter.com/BazaarMrb

Follows to Linkdin :https://www.linkedin.com/company/market-research-bazaar-vrrb/

Visit link:
Male Breast Cancer Market 2020 By Key Features, Advancements, Development, Rapid Growth, Companies Profile, Technology, Industry Verticals And...

Recommendation and review posted by Bethany Smith

UNSW Sydney

The average size of a dingo is increasing, but only in areas where poison-baits are used, a collaborative study led by UNSW Sydney shows.

Dingoes have gotten around 6-9 per cent bigger over the past 80 years, new research from UNSW and the University of Sydney shows but the growth is only happening in areas where poison baiting is used.

The scientists measured the skull size which is a marker of animal size of nearly 600 dingo specimens originating from the sites.

This equates to roughly a kilogram in body mass.

While both male and female dingoes grew, female dingoes had the biggest growth spurt: their skulls increased by 4.5 millimetres, which is almost 9 per cent body mass. Male skulls grew by 3.6 millimetres, or 6 per cent body mass.

The question is: why are dingoes in poison-baited areas growing?

He explains that dingoes primary prey, kangaroos, have been shown to increase in numbers when dingo populations are suppressed.

With more food in abundance, dingoes physical growth is less restricted.

The pesticide sodium fluoroacetate known as 1080 (pronounced ten eighty) is commonly used across Australia to control dingo and other pest populations.

A flavourless white powder, 1080 is usually stuck into meat baits and left in dingo hotspots, often via helicopter drops. Baiting was rolled out in Kalgoorlie, Pilbara and pastoral South Australia over the 1960s and 70s.

Dingoes from the unbaited region which included Indigenous-owned lands and conservation reserves saw no change in body size.

This is not the first time a pesticide has been linked to changes in animal bodies.

Our interventions have consequences and theyre actually quite predictable consequences, says Prof. Letnic.

Whatever pressures we put on animal populations be it pesticides or not there will be side effects.

Scientists usually observe these impacts in invertebrate pests: for example, some insects like cockroaches are becoming more resistant to the insecticides used on them.

However, this study is one of the first to show that vertebrates, like dingoes, also change from pesticide use.

Poison baiting campaigns could be favouring the survival of larger dingoes, says A/Prof. Crowther.

Smaller dingoes need less poison for a lethal dose, so are more likely to be killed by baiting. This leaves the larger dingoes to survive and breed.

As a result of their growing size, the 1080 dose required to kill a dingo in the baited regions has increased since the toxin was introduced.

The reaction to this finding may be to add more poison to the baits, or to find a new poison, says Prof. Letnic.

But, eventually, the cycle will start again.

The exact mechanisms at play are still unclear but a greater abundance of food post-baiting and dingoes adapting to the poison are likely the most influential factors.

Other factors that could have potentially led to the dingoes growth, like climate change or interbreeding with dogs, seem unlikely.

We only tested dingoes in areas that have very low dog hybridisation rates, making it highly unlikely that dog genetics are contributing to the size growth, says Prof. Letnic. Most dingo-dog hybridisation, he explains, occurs on the east coast of Australia.

The researchers also suggest that if anything a warming climate would decrease dingoes body size, as cooler conditions favour larger animals.

Further studies that use a broader sample of dingoes from across Australia could help better understand the cause of the dingo body change.

In the meantime, the researchers hope to explore other ecological impacts of 1080 baiting.

Baiting is changing dingoes, so it could be changing other animal populations, says Prof. Letnic.

Animals respond to human interventions, whether directly or indirectly. The changes could well be adaptive, and we must think about that.

/Public Release.

View post:
Dingoes have gotten bigger over last 80 years - and pesticides might be to blame - Mirage News

Recommendation and review posted by Bethany Smith

Arguably, one of the most life-altering medical procedures that a woman can undergo is a hysterectomy. For those who are not familiar with hysterectomies, they are surgical procedures that entail removing a womans uterus and, in some cases, other reproductive organs. When this happens, her menstrual cycles will stop, and she will lose the ability to get pregnant. According to a study published by the Centers for Disease Control and Prevention (CDC), an estimated 600,000 hysterectomies are performed in America every year, with the average woman getting one around the age of 42.

The success rate for hysterectomies is quite high for women who undergo them to combat specific health problems, some of which include fibroids, pelvic pain, endometriosis, and a prolapsed uterus. Hysterectomies are also sometimes recommended to women diagnosed with cancer of the uterus or cervix.

When it comes to hysterectomies, the end of a womans menstrual cycles and an inability to get pregnant represents only a part of what she can expect after surgery. Before detailing the additional side effects that a woman is likely to encounter, lets take a moment to go over the three types of hysterectomies that a physician might recommend depending on the health condition their patient is facing:

Partial hysterectomy This surgical procedure entails removing a womans uterus while leaving her cervix intact.

Standard hysterectomy This surgical procedure entails removing both the uterus and cervix.

Total hysterectomy This surgical procedure involves removing the uterus and cervix. Additionally, the surgeon will also remove one or both ovaries as well as the fallopian tubes.

Regardless of the type of hysterectomy procedure a woman undergoes, she will likely encounter an array of short-term side effects afterward. Some of these short-term side effects can include the following:

Although short-term side effects will typically resolve themselves, women who undergo a total hysterectomy may encounter long-term side effects that sometimes require additional medical treatment. A few of these long-term side effects, which are also commonly associated with menopause, include the following:

Many women who undergo a hysterectomy often find themselves struggling with hormonal deficiencies. And this is especially true following a total hysterectomy. According to Science Daily, an online aggregator of science-related press releases, total hysterectomies can increase the risk of early menopause in younger women by nearly two-fold. In short, this means that women who undergo these types of hysterectomies, in addition to hot flashes, insomnia, night sweats, vaginal dryness, and low libido, may experience hormonal imbalances as well. In fact, some women who undergo a hysterectomy that includes the removal of one or both ovaries experience a sharp decline in estrogen and progesterone production. This decline is triggered by a severe drop in human growth hormone production, which, unfortunately, is yet another side effect of undergoing a hysterectomy for many women.

To combat many of the side effects that follow a hysterectomy, many women turn to human growth hormone (HGH) replacement therapy. This form of therapy, administered by injection, provides the same level of symptom relief to women following a hysterectomy that it does to menopausal women. Considering that low growth hormone levels often lead to low estrogen and progesterone levels, it makes sense that many physicians are recommending growth hormone replacement therapy alongside traditional treatments consisting of estrogen and progesterone replacement therapies. Some physicians are even recommending growth hormone replacement therapies over estrogen and progesterone since they are less likely to result in complications.

For reference, a study published by the National Cancer Institute found that estrogen replacement therapies can increase a womans chances of developing blood clots, gallstones, or suffering a stroke. Further, when combined with progesterone or another bioidentical hormone, such as progesterone, can increase the risk of developing breast cancer.

When it comes to hormone replacement therapy involving the use of growth hormones to combat the side effects of a hysterectomy, the long and short of it is that these treatments help return a womans growth hormone levels to a healthy and normal state. In response, her estrogen and progesterone levels return to a normal and healthy state as well. Once her growth hormones, estrogen, and progesterone levels are normalized, the side effects that follow a hysterectomy, such as night sweats, low libido, hot flashes, and low bone density, for example, will start to subside. Further, her chances of developing breast or uterine cancer will also decrease. Some of the more commonly prescribed HGH-based medications that physicians prescribe to women following a total hysterectomy include the following:

If youre thinking about starting HGH-based replacement therapy to relieve side effects following your hysterectomy, youre probably interested in knowing how long it will take to see results. If so, you will be happy to know that, for most women, these treatments begin to work almost immediately. However, long-term improvement of symptoms can take anywhere from 3 to 6 months.

In summary, even though human growth hormone replacement therapy is a relatively new approach to combating side effects brought on by a hysterectomy, there is evidence that proves it is just as effective as estrogen hormone replacement therapy. More than that, it is significantly safer by comparison, according to most physicians.

See the article here:
HGH and Hysterectomy: How Does Hormone Therapy Help? Read more / Skip - eTurboNews | Trends | Travel News

Recommendation and review posted by Bethany Smith

Periods are just one of the amazing functions of the female body. And while we're all probably familiar with what a period is, you might not know quite so much about a withdrawal bleed (AKA a period you have while taking hormonal contraception)? So, whether you've had a withdrawal bleed before, or you're considering starting on birth control, here's everything a doctor wants you to know about withdrawal bleeding.

A withdrawal bleed is essentially the period that you have while you're on hormonal birth control. But how does it work? Here are the basics:

"Many types of contraception work by altering your bodys hormones, preventing your ovaries from releasing an egg each month," explains Dr Samantha Wild, a GP and Primary Care Physician at Bupa Health Clinics. A lot of these hormonal birth controls, like the pill, patches and vaginal rings, work on a 21-day cycle, giving you a week off taking hormones which is when you have the withdrawal bleed. And there's a purpose to this intermittent bleeding. "A 'withdrawal bleed' happens as a result of this drop in hormones when you have the week off, and the body releases some of the blood and mucus from the lining of the uterus," Dr Wild explains.

For all intents and purposes, you might think a withdrawal bleed is the same as a period - it looks the same, anyway. But it's not. "Withdrawal bleeding isnt the same as a regular period. This is because the hormones from the contraception affect your endometrium the lining of your uterus preventing it from thickening, so theres less discharge," notes the doctor.

"Similarly, the hormones also prevent you from ovulating, meaning there is no egg for your body to get rid of. As such, withdrawal bleeds are typically lighter and have less pronounced symptoms to a standard period, Dr Wild adds.

It's not just the pill that can cause withdrawal bleeding. Other kinds of hormonal contraception usually contain the same hormones and have the same effect - they're just inputted into the body in a different way.

"Contraceptive patches work in the same way as the pill and contain the same hormones, oestrogen and progestogen, and the same goes for the contraceptive vaginal ring which is inserted in the vagina," Dr Wild explains. "But pills, patches and vaginal rings are the only types of contraception which may cause withdrawal bleeding. You wont experience one when using the coil," she advises.

This is because, on the copper coil (IUD), you still get your normal monthly period. "The IUD doesnt contain any hormones. Your regular period may be heavier, longer or more painful especially in the first 3-6 months after it is put in," says the doctor. "The Intrauterine System (IUS) wont cause a withdrawal bleed either. This is a small plastic T-shaped device that releases the hormone progestogen into the womb to stop you getting pregnant. It can make your periods lighter, shorter or stop altogether. These arent withdrawal bleeds though, as the progestogen is provided constantly so theres a no break in the cycle." So there you have it.

As with 'normal' periods, withdrawal bleeds vary from person to person, and everyone's cycle is different. However, they will usually average at just under a week. "Withdrawal bleeding happens when you are having one week with no hormones," explains Dr Wild, "but the bleed will usually last for less than a week as it can take a couple of days to start after the hormones have stopped going into your system."

"You might still experience some symptoms similar to those you get around your 'normal' menstruation, but they are usually less severe," says Dr Wild. So, hopefully, even if you've still got cramps they won't be as tough as usual.

Plus, hormonal contraception like the pill is actually often prescribed as a treatment for PMS because the symptoms are milder, Dr Wild adds, so if you're struggling with PMS then switching to hormonal contraception with a withdrawal bleed could actually be a good option. But, of course, speak to your doctor first.

Ashley Armitage / Refinery29 for Getty ImagesGetty Images

Although pill packets are usually designed to give you a break (and therefore a withdrawal bleed) once a month, you actually don't need to take one. "It's not medically necessary to have a withdrawal bleed every month," Dr Wild explains. "Early pill regimes were designed like this to mimic a natural menstrual cycle, but it's safe to take them for longer before having a break."

Taking pill packets back to back without having a break will mean your withdrawal bleeds become less frequent. And if you do still experience symptoms during your withdrawal bleeds, then you most likely won't have any of these symptoms while taking packets without a break.

However, Dr Wild advises speaking to your GP before you make any changes to how you take your pill, as you'll need to make sure it's right for you.

The short answer is yes. "A withdrawal bleed is still a sign that you're not pregnant," says Dr Wild. And on the flip side, "if you don't bleed when you expect to then you should do a pregnancy test, if there is a chance that you could be pregnant."

However, some people don't have withdrawal bleeds, adds Dr Wild, and if you're not having a pill break then you won't have one either - so you won't be able to use bleeding/not bleeding as an indication. Other first signs of pregnancy include "breast tenderness, nausea or fatigue," says Dr Wild, but if you suspect you could be pregnant then still take a test.

Like this article? Sign up to our newsletter to get more articles like this delivered straight to your inbox.

SIGN UP

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

Continued here:
Withdrawal bleeding - what is a withdrawal bleed? - cosmopolitan.com

Recommendation and review posted by Bethany Smith

Around menopause, many women have at least occasional difficulties when it comes to sleep. Experts often attribute this to changing hormones or to the stress and anxiety that may accompany midlife.

A new study adds another potential factor to the mix: endocrine-disrupting environmental chemicals (EDCs), especially phthalates.

Related:11 Natural Insomnia Aids That Will Give You Sweet Dreams

This study is important because endocrine-disrupting chemicals are everywhere, says Stephanie Faubion, MD, a womens health physician at the Mayo Clinic in Jacksonville, Florida, and the medical director for the North American Menopause Society (NAMS). It provides additional evidence of potential sex differences in endocrine disrupting chemical exposure (in this case, phthalates) and impact on health.

The study was published on July 29, 2020, in the NAMS journal Menopause.

RELATED:10 Ways to Beat Menopausal Belly Fat

Researchers at the University of Illinois used information from the Midlife Womens Health Study. This major clinical trial was conducted between 2006 and 2015 with women ages 45 to 54 in the Baltimore region, to assess risk factors for hot flashes in women not taking hormone therapy. Because the women were tracked closely for so many years, others researchers have subsequently mined its health data to shed light on other issues surrounding menopause.

For this study, data from 760 premenopausal and perimenopausal women were assessed. Questions the women had answered about sleep, among other things, were matched with concentrations of chemical phthalates in their urine.

The scientists focused on phthalates because a previous study had suggested increased exposure to the chemicals significantly increases a womans risk of hot flashes. Animal studies have also shown its influence on hormones associated with sleep.

Related: Fight Menopausal Sleep Problems With Light Therapy, Study Suggests

The results confirmed that the frequency of sleep disruptions in midlife women is associated with higher concentrations of phthalates in the body.

The relationship proved to be complex, however, and may be affected by other factors, especially smoking. Because smoking is known to impact both sleep and hormones, women with the same levels of chemicals who were former smokers reported different effects on their sleep than nonsmokers. This suggests that smoking history influences the relationship between phthalates and self-reported frequency of disrupted sleep, the authors write.

Still, anything that sheds light on possible reasons for sleep disturbances will be welcomed by many midlife women.

Up to 60 percent of women in their menopause transition report sleep issues, the study authors note. They also point out that women who have trouble falling asleep are at increased risk of developing depression.

Because this was an observational study and not a randomized clinical trial, and because of the confounding influence of smoking, additional study is needed investigating the complex relationship between endocrine disrupting chemicals, hormones, and sleep, mood, and menopause symptoms, Dr. Faubion says.

She also notes that other factors known to impact sleep were not measured in the study, including caffeine intake and stress, which may have influenced the results.

Whats more, the underlying mechanisms by which EDC exposure impacts sleep in midlife women still need to be uncovered, the researchers write.

RELATED: Why Sleep Is an Important Womens Health Issue

Even before that research is done, though, experts say its smart for all women, including those in midlife, to minimize phthalate exposure as much as possible. The chemicals appear to concentrate more in women than men, the study authors note.

Phthalates are common EDCs that are used in a wide array of industrial products to increase their performance, explains Nneka Leiba, MPH, vice president of healthy living science at the nonprofit Environmental Working Group in Washington, DC.

RELATED: 10 Toxic Household Items You Should Throw Away Now

They can be found in plastics and food packaging, Leiba says. A key way midlife women come into contact with them is through skin-care products.

Phthalates are used as ingredients in personal care products, including skin-care products, perfumes, and colognes, she says. And since they are typically part of any products fragrance mixtures, you are also likely to encounter them in anything with an aroma, from candles to detergents to trash bags, she says.

Black women may be at higher risks than white women for exposure to these chemicals. EWGs research indicates that Black women use more personal care products than other demographics, and there are fewer productsmarketed specifically to Black womenthat are free from chemicals, Leiba says.

RELATED: What Are 'Natural' Skin-Care Products, and Are They Actually Better for You?

Due to their pervasiveness, it isnt possible to avoid phthalates completely. Even limiting your exposure would mean knowing which products theyre hiding in, something that is difficult because manufacturers are not required to label these ingredients, Leiba says.

Given that phthalates are often used in fragrances, Leiba suggests avoiding products that bear the catch-all label of fragrance. Instead choose products that disclose specific fragrance ingredients. You can even contact a manufacturer to ask about their use of phthalates in your favorite products, she advises.

EWGsSkin Deep database identifies many skin-care options without these and other ingredients of concern.

For any product, if you come across a brand labeled phthalate-free, choose it to help lower your risk of EDCs, advises the medical organization the Endocrine Society.

See the original post:
Can Toxic Chemicals Trigger Sleep Trouble? - Everyday Health

Recommendation and review posted by Bethany Smith

Federal officers deploy gas to disperse crowds of protesters near the Mark O. Hatfield federal courthouse in Portland, Ore., July 20, 2020.

Jonathan Levinson / OPB

After more than 50 days of nightly protests against racism and police violence, demonstrators in Portland are intimately familiar with the immediate effects of tear gas: blurry eyes, burning skin, choking, coughing, crying, retching.

But some protesters believe the gas is doing more than causing red eyes and seething skin. OPB interviewed 26 protesters, ranging in age from 17 to 43, who said they believe regular exposure to tear gas has caused irregularities within their menstrual cycle.

Related: 60+ days of tear gas leaves behind 'a stew of pollutants'

The experiences range. Some protesters reported getting their period multiple times in a single month. Others reported debilitating cramps at least one that ended in a hospital visit and blood clots the size of half a fist. Trans protesters who had stopped menstruating since taking testosterone said they have seen their cycles restart.

There are two common threads between the experiences of the 26 protesters: All said what they were experiencing was abnormal for their bodies. And all believed the tear gas, which law enforcement has been using against demonstrators for two months, was at fault.

Related: 60-plus days of tear gas leaves lingering questions about environmental impacts

There has been little scientific research into whether tear gas can affect a persons hormones and experts warn against extrapolating a solid medical conclusion from anecdotal evidence. But while the science remains thin, the troubling stories have mounted as the release of the chemical has become a near-nightly occurrence.

Lindsey Smith, a 26-year-old preschool teacher who has been live-tweeting the protests since mid-June, said shes noticed a pattern: If she inhales a significant amount of gas in the night, shell have her period the next morning. She said this has happened at least three times in two months even though the hormonal birth control shes on makes it so shes only supposed to menstruate four times a year.

On July 12, after another night that saw federal officers blanket the crowd with tear gas, Smith tweeted to ask if anyone else was menstruating after being exposed to the gas. She received nearly 30 responses from protesters with their accounts of irregular periods: cramping within hours of exposure, periods that stretched for nearly a month, or arrived weeks early.

She was also met with some trolls.

When I posted that, there were a lot of alt-right people screenshot-ing it and reposting it and a lot of them are saying, Good, I hope after this youre sterile, she said. That was the first time that the thought occurred to me: I dont know what this is going to do. And I dont think anyone really knows long-term.

Within the small body of research that does exist on tear gas, the question of what effect it could have on a persons reproductive health, if any, has been left unanswered.

Sven Eric Jordt, an associate professor at the Duke University School of Medicine who has extensively studied tear gas agents, said its possible the gas impacts hormones. He pointed to a 2010 study that showed burning the agent in CS gas, a common type of tear gas, could generate chemicals potentially toxic enough to affect hormonal homeostasis. Researchers in Chile raised concerns tear gas might cause miscarriages in 2011, leading the government to temporarily ban its use. In Bahrain, Physicians for Human Rights documented accounts of pregnancy loss among civilians gassed during anti-government protests.

But no one can say with certainty if theres a link.

Theres really no data on this. Its entirely possible that some of these chemicals that if you inhale them at high levels can have effects, Jordt said. But its really hard to say.

Intense stress could be another culprit. Rising levels of cortisol, the bodys primary stress hormone, are known to upend normal menstrual cycles, And the policing tactics common among local and federal officers including tear gas, impact munitions, and flash bangs could all be fairly described as cortisol-inducing. Not to mention the new unusual rituals that could potentially alter someones usual menstrual cycle: bedtimes pushed to the early morning, a diet of snacks and energy drinks, nightly sprints away from gas and police.

But some protesters in Portland are convinced that stress alone cant explain their experiences.

While many nights are traumatic, protesters are not breathing lungfuls of the chemical every single evening. And some report its only in the aftermath of these hazy nights, during which theyve inhaled for minutes without a mask, that they notice the irregularities.

Alissa Azar, 29, has been protesting downtown at least five nights a week since the demonstrations began. She said shes been caught in the thick of a cloud of gas six times. On two of these occasions, her period started immediately after. The other four times, it started within a few days.

Obviously were experiencing a significant amount of stress right now physically, mentally, emotionally. It would be naive to believe that doesnt have an effect. However, I definitely think theres a correlation between menstruation and tear gas, she said. The timing has been too spot-on.

She said the periods are different than what she expects. Each one lasts for four or five days. The cramps are more like the contractions she had when she gave birth, inducing nausea and severe back pain. A dozen other protesters interviewed had similar accounts of cramps that felt like sharp rocks being cradled in their stomachs.

Were not paranoid. This isnt a coincidence. Somethings going on, Azar said. Within 15 minutes of a gas attack, myself and others will have to take a break from how bad the cramps are.

For some, the experience goes beyond physical pain. Five transgender individuals taking testosterone, which typically stops menstruation after a matter of months, told OPB theyd seen their cramps and bleeding return after attending demonstrations.

These protesters say these unexpected periods were accompanied by a sense of gender dysphoria, the clinical term for the discomfort and distress people feel when their bodies dont align with their gender.

Its definitely a back and forth feeling. Im still pretty early in my transition, and Ive waited a really long time to be able to do this, said Lester Lou Wrecksie, a nonbinary transmasculine person who has been taking testosterone since September.

Wrecksie, 43, said on most nights they stay in the back of protests, largely out of the way of gas. But on June 21, they got knocked down and ended up getting caught in the chemical for longer than usual. Two days later, Wrecksie said their cycle returned for the first time in half a year.

Its unsettling to be like, I can go out into the air with chemicals and have it basically undo part of what Im trying to do for myself, they said.

A few protesters said they were concerned enough with the period irregularities that they scheduled a call with the local Planned Parenthood. Paula Bednarek, the medical director for Planned Parenthood Columbia Willamette, said clinicians had not noticed an uptick in patients reporting unusual menstruation since the protests began.

But enough reports linking period irregularities and tear gas have cropped up nationwide in the last few months that another branch of Planned Parenthood has taken note. An epidemiologist with Planned Parenthood North Central States, which supports reproductive health in Iowa, Minnesota, Nebraska, North Dakota, and South Dakota, crafted a research proposal after putting out a call for reports from protesters whod spontaneously menstruated after being tear-gassed. A handful of online outlets have also done write-ups this summer questioning a possible connection between the chemical and periods.

Dr. Rohini Haar, a medical expert for Physician for Human Rights, said while these experiences should be acknowledged, she believed there is danger in overreporting a potential link without the hard scientific evidence to back it up.

Haar, an expert in crowd control weapons who has studied the health consequences of tear gas up close among Palestinian refugees, said shed only started hearing these anecdotal reports of tear gas affecting menstruation a few weeks ago. She worried these new accounts could genderize protests and lead to a narrative that protesting is only safe for people without ovaries.

This may be an issue, but its certainly not enough of an issue to intimidate people away from protesting especially women, she said. Its not the situation where you should tell your teenager, This definitely injures your reproductive tract, you are not allowed to go. There is no evidence to say that.

Dr. Jordt said he thought it would be worth trying to find out. He suggested a local or state health department in Oregon should initiate a study, taking health data from protesters and residents and following up with them over the long term.

Jordt estimates there are currently five or six of these sorts of studies that look at long-term effects of tear gas on people who have been exposed repeatedly, most coming from the Middle East during the Arab Spring. But he said governments in these countries often hampered the efforts of the doctors leading these studies, making it difficult to follow up with civilians over long periods of time.

One of the most comprehensive studies within the United States was conducted on recruits for the U.S. Army in 2014. Researchers found recruits exposed to CS gas as part of a training exercise were at a higher risk for developing respiratory illnesses, including influenza, pneumonia and bronchitis.

They were exposed to the gas just once.

Jordt pointed to two reasons why learning the long-term health effects of repeated exposure to tear gas has yet to become a top concern of health experts in the United States: The first is that its rarely used at the levels the country has seen this summer. While its been used en masse on protesters before in Ferguson, Missouri, in 2014, during the Occupy Wall Street movement in 2011, during the Vietnam War protests in the 60s and 70s he said the chemical hasnt been pervasive enough to become a top priority among health experts.

Nor is it top of the list for law enforcement agencies. Jordt said theres a strong belief among law enforcement that teargas is their safest option for controlling crowds. He suspects they will not be the ones leading the charge for a deeper study.

The lack of concrete studies has left some protesters feeling like guinea pigs, scouring Google for answers on whats happening to their bodies with no satisfying results.

We dont know the long term effects of this, said Elisa Blackman, 24, who said she got her period five times between June 2 and July 5. She tried to search for an explanation, but the hits she got on the internet focused on effects you could expect in the minutes after being gassed, not weeks or years.

Its like theyre testing it on us.

Read more here:
'It's like they're testing it on us': Portland protesters say tear gas has caused irregularities with their periods - OPB News

Recommendation and review posted by Bethany Smith

The most up to date shrouded weapon in your wellbeing stockpile may simply be the kelp you ventured over to get into the sea the last time you were at the sea shore. Ocean greenery has been around since the seas previously lapped the shore, yet its getting a charge out of a flood in notoriety, on account of its incredible invulnerable boosting supplements. Ocean greenery is plentiful in common minerals, high in iron and cancer prevention agents that make it an inside and out insusceptibility promoter and weight reduction help, which is the reason organizations are gathering it from sea shores as far away as Ireland and the Caribbean, and purchasers are adding it to everything from smoothies to acai bowls and rice and beans.

It is difficult to distinguish one specific plant that has all the nutrients and minerals your body needs, however ocean greenery approaches. It contains over 90% of the supplements your body needs and can be utilized as a characteristic medication to treat or lessen influenza like side effects. This is the reason the little ocean plant is regularly called Natures Multi-Vitamin.

Ocean Moss, otherwise called Irish Moss, is a kelp, is a large scale green growth. It is sold in packs that look simply like the clear yellow ocean growth youd discover appearing on sea shores along the Atlantic seaboard and the Caribbean. Ocean greenery originates from both natural gathering and man-made pools, and where its developed influences the organization of the plant and its medical advantages. Crucial Vegan accepts that wildcrafted ocean greenery from the sea is better, so they just collect their ocean greenery from the Caribbean, explicitly Jamaica.

Under two centuries prior, ocean greenery was utilized as a wellbeing treatment of tuberculosis and pneumonia. Its likewise been utilized as a food to sustain individuals who worked in potato fields since it was a modest wellspring of supplements. Since it was utilized by helpless ranchers, the kelp was thought of as a poverty food, and overlooked by wellbeing searchers, because of the negative affiliation. Dr. Sebi, the notable botanist with the clique like after, took ocean greenery back to the consideration of his adherents and prescribed it to his patients to treat ceaseless diseases. Presently standard, ocean greenery is accessible at wellbeing markets and online through organizations that develop it in sea pools and reap it to sell.

Creator and veggie lover botanist Paul Otote clarified the medical advantages of ocean greenery and why this kelp is viewed as a powerhouse food. The Beet recorded his six motivations to eat ocean greenery, so you can completely comprehend why this supplement thick food is valuable for generally speaking wellbeing.

1. Ocean Moss Contains Iron and Can Help You Have More Energy.

Ocean greenery is loaded with iron, which many plant-based eaters need since its generally found in creature nourishments like meat, poultry, and fish. Ocean greenery contains around 9 milligrams of iron for every 100 grams, which implies ocean greenery has multiple times more iron than chicken. At the point when youre feeling exhausted or low vitality, it might be on the grounds that your iron levels are low, since iron enables your body to make red platelets to move oxygen from your lungs to your cells. On head of taking a sound iron enhancement, take a stab at including ocean greenery in a gel structure to your smoothies and check whether you start to see the distinction in your vitality. In the event that you have ever been determined to have mellow weakness, ocean greenery could work to enable your body to get the iron you need.

2. Ocean Moss Contains More Tha 90% of Nutrients Our Bodies Need.

The small winding yellow ocean growth is amazingly supplement thick, its practically similar to natures multi-nutrient. Otote clarifies that sea moss has 92 of the 110 minerals the body is made from, and he considers it the powerhouse. Sea greenery contains beta-carotene, nutrient B, nutrient C, and sulfur just as minerals like magnesium, manganese, calcium, phosphorus, and zinc. All these add to solid cell working in the body.

3. Ocean Moss Promotes Healthy Weight Loss.

Ocean Moss contains elevated levels of iodine, a mineral found in a constrained measure of nourishments. Our bodies need this mineral with some restraint to create thyroid hormones. These hormones control the bodys metabolism and many other important functions. The body also needs thyroid hormones for proper bone and brain development during pregnancy and infancy, as per an examination by the National Institute of Health. The key is to get the perfect sum, in any case, and not all that much.

Ocean Moss contains the indispensable thyroid hormone precurses that are significant for solid thyroid capacity and your bodys digestion. So if your thyroid isnt working appropriately they can be valuable and help in weight reduction. In any case, before you use ocean greenery to support thyroid hormones or as a weight reduction supplement, check with your primary care physician since you would prefer not to over-do these hormone forerunners either. Control is the most significant thing with thyroid capacity.

4. Ocean Moss Can Help You Build Strong, Lean Muscles.

The ocean growth is wealthy in protein with 6 grams of protein for each 100 grams of ocean greenery. In particular, it contains an amino corrosive called taurine, which enables the body to consume fat and assemble muscle. Taurine has the ability to make the body burn fat instead of carbs during cardio, Otote says.

5. Ocean Moss Strengthens the Immune System and Helps to Prevent Sickness.

Ocean Moss likewise enables the body to retaliate against regular maturing and irritation, in what could be classified the antis: Anti-provocative, hostile to maturing, against bacterial, and against viral. Its utilized as a treatment to help forestall and soothe cold and influenza like side effects, in powdered structure. It can be used to prevent colds but also help you heal and recover from sickness, Otote says. Ocean greenery contains potassium chloride, which enables the body to lessen irritation and individuals take it to bring down their danger of contaminations as a result of its positive effect on the invulnerable framework. Otote summarizes it as a no-lose added substance: Sea moss when youre ill is a win, and sea moss when youre healthy is a win, its a win-win.

Ocean greenery can be taken in a gel fluid structure to add to your smoothies, acai bowl, or even applied legitimately to your skin or hair as a lighting up treatment. The kelp can likewise be utilized as a preparing subsite for eggs, which makes is a simple method to get minerals into your eating routine through heating so use ocean greenery when you heat treats, cakes, and biscuits. You can likewise utilize it as a roux or a thickening gel in grains like rice or quinoa, farro, or when making beans.

Greg Mulligan is a well-known author and publisher. He published few article on his career. His secret ambition on arriving in Paris was to become a successful writer. Mulligan is winning multiple awards for his excellent writing, In addition to his regular contributions to English journals and articles. Presently he is working on Broadcast Cover.

See more here:
Sea Moss: Add To Your Diet For Natural Weight Loss, Better Immunity and Energy - Broadcast Cover

Recommendation and review posted by Bethany Smith

Getty Images

Most of us have a cabinet full of supplements that at some point, get neglected. Whether it's because you fell out of your routine or you forgot why you even started it in the first place, there's one that most Americans could benefit from adding back into their regimen: magnesium.

Studies show that the majority of the population is at risk for magnesium deficiency due to a variety of lifestyle factors, including a diet high in processed food. Certain illnesses or health conditions, including Type 2 diabetes or alcohol dependency, can make you susceptible to low magnesium levels, too. A 2013-2016 analysis from the National Health and Nutrition Examination Survey found that 48% of Americans don't get adequate magnesium in their diets.

Our Health & Wellness newsletter puts the best products, updates and advice in your inbox.

Magnesium supplements have become popular in the wellness space recently, and many experts are recommending them for helping with sleep, stress, anxiety and more. But do these claims hold up? Below, I give an overview of the science on magnesium, and I also talked to registered dietitian Amy Gorin to find out more on why magnesium is important and how to know if a supplement may be right for you.

Magnesium requirements vary based on a person's age, gender and other health factors (like pregnancy), but the average recommendation is around 300mg per day.

"Magnesium is important for so many aspects of health. The mineral is involved in more than 300 enzymatic reactions in the body. It's important for bone health, helping to keep your blood sugar levels stable, helping your muscles and nerves to properly function, and keeping your blood pressure at healthy levels," Gorin says.

Magnesium levels also affect your brain and your mood, which is why low levels of magnesium are associated with mood disorders, although more research needs to be done to determine just how important it is for your emotional or mental health.

If you've ever asked a health expert about the best supplements for stress, chances are magnesium is on the list. Why? First of all, according to Gorin, magnesium helps the brain cope with stressors. "Research has shown that magnesium supplementation may affect the brain functions that help lower stress and anxiety," Gorin says.

It works by helping your body kick into the "rest and digest" state, or by activating your parasympathetic nervous system. When you are stressed, your body is likely in the sympathetic nervous system for prolonged periods, which over time can make you feel run down and tired. Studies also showed that magnesium intake helped improve heart-rate variability (HRV) scores, which are representative of how well your body can adapt to stress.

Likewise, magnesium can help you sleep better, since the mineral can have a calming effect on your body. Magnesium helps regulatethe hormone melatonin, which is involved with controlling your circadian rhythm. Your circadian rhythm regulates many things in your body, including when you feel tired and how well you sleep.

Many activities and habits can throw off your circadian rhythm, including exposing your eyes to blue light at night. If you are trying to optimize your circadian rhythm, or are trying to get better sleep with melatonin supplements, you should check that your magnesium levels are optimal since they work together to help you get better rest.

A 2017 study reviewed the connection between magnesium and exercise performance, and found that the more active you are, the more your body needs magnesium. Some claim that it can help you recover faster from workouts, but the evidence on magnesium specifically for workout recovery is limited.

We do know that your muscles need adequate magnesium to function well and avoid cramping, so it makes sense that optimal magnesium levels can facilitate better recovery from workouts.

Grains and seeds contain naturally occurring magnesium.

Vitamin D is crucial for your overall well-being and especially for your immune system health. But even if you think you're getting enough vitamin D through supplementation or sun exposure, you could still be low if your magnesium levels are not optimal.

According to the American Osteopathic Association, low magnesium levels can make vitamin D ineffective. That means that even though you are taking in vitamin D from food, supplements or sunlight exposure, your body can't use it or benefit from it unless you have sufficient magnesium levels.

Magnesium is found naturally in food, like leafy vegetables, whole grains, nuts, seeds and milk, but it's usually in smaller amounts and it can be difficult to get the full 300 mg or more that is needed per day. Plus, scientistspredict that only about 30% to 50% of the magnesium that you take in is actually absorbed in the body. For these reasons, many people turn to a supplement to ensure they are meeting their daily needs.

There are several different types of magnesium supplements that can help specific issues.

If you walk into a vitamin or health food store and look for magnesium supplements, you will likely find several different types. You can get magnesium supplements in powder form (like the popular Natural Vitality Calm supplement) that can be dissolved in water or you can take the mineral in a capsule or tablet.

But not all magnesium supplements are the same, which is why it's important to not only seek a health professional's guidance on which supplement may be best for you, but also understand that different forms of magnesium can have different side effects. For example, magnesium carbonate is one form of magnesium that, if you overdo it, you can end up with stomach upset and diarrhea.

Popular forms of magnesium that are available in supplements:

Magnesium glycinate:"This is a common form of magnesium in supplement form. You might also see it used in heartburn treatments," Gorin says. Magnesium glycinate is often recommended by experts since it's absorbed well in the body and tends to cause less stomach discomfort or upset.

Magnesium oxide: "This form of magnesium can be used as an antacid for heartburn relief, as a short-term laxative, or as a dietary supplement when you're not taking in enough magnesium from food," Gorin says.

Magnesium citrate: "This form of magnesium is sometimes used as a stool softener or laxative," Gorin says.

Magnesium L-threonate:"This is a specific type of magnesium that's been proven to have cognitive benefits. It was discovered by MIT researchers, and you can get it in supplement form. Research suggests that it may help improve brain plasticity, which may have positive effects on memory, learning and cognition," Gorin says.

Now playing: Watch this: Telehealth will be the new normal after the pandemic

26:07

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.

More:
Magnesium: Why you need this mineral for better sleep, mood and more - CNET

Recommendation and review posted by Bethany Smith

By David Fierro and Matthew Brown

Meghan Lynch participates in the "Buoy-to-Buoy" swim at Rocky Point Club in Old Greenwich, Connecticut on August 1, 2020. The Swim Across America Event organized by Team Julian, honoring the legacy of Greenwich's own Julian Fraser, who lost his life battling a rare form of cancer, raised over $45,000 for cancer research. Over 50 swimmers from Rocky Point Club and Greenwich High School's Swim and Water Pola teams participated in the 1-mile swim in the Long Island Sound. Several volunteers in kayaks and on paddle boards, Including Julian mother, Cristy Fraser, kept watch over the group during the benefit swim.

Meghan Lynch participates in the "Buoy-to-Buoy" swim at Rocky Point Club in Old Greenwich, Connecticut on August 1, 2020. The Swim Across America Event organized by Team Julian, honoring the legacy of

Photo: Matthew Brown / Hearst Connecticut Media

Meghan Lynch participates in the "Buoy-to-Buoy" swim at Rocky Point Club in Old Greenwich, Connecticut on August 1, 2020. The Swim Across America Event organized by Team Julian, honoring the legacy of Greenwich's own Julian Fraser, who lost his life battling a rare form of cancer, raised over $45,000 for cancer research. Over 50 swimmers from Rocky Point Club and Greenwich High School's Swim and Water Pola teams participated in the 1-mile swim in the Long Island Sound. Several volunteers in kayaks and on paddle boards, Including Julian mother, Cristy Fraser, kept watch over the group during the benefit swim.

Meghan Lynch participates in the "Buoy-to-Buoy" swim at Rocky Point Club in Old Greenwich, Connecticut on August 1, 2020. The Swim Across America Event organized by Team Julian, honoring the legacy of

Greenwich swimmers take the plunge to fight cancer

GREENWICH A team of over 50 swimmers and 15 volunteers joined forces to raise more than $45,000 in the fight against cancer and to honor a 2014 Greenwich High graduate and standout swimmer who died of osteosarcoma.

The group known as Team Julian team gathered Saturday at Rocky Point Club in Old Greenwich for the endurance swim on Long Island Sound to benefit Swim Across America Fairfield County.

The event honored the legacy of Julian Fraser, who lost his battle with a rare form of bone cancer in 2017 at the age of 20.

The swimmers from Rocky Point Club and Greenwich High School's Swim and Water Pola teams participated in the 1-mile swim in the Long Island Sound. Several volunteers in kayaks and on paddle boards, including Julian Frasers mother, Cristy Fraser, kept watch over the group during the long benefit swim.

Julian Fraser earned All-America honors as a swimmer and water polo player. He competed on numerous championship teams for GHS coach Terry Lowe, then excelled on the Santa Clara University water polo team.

We are united to raise money for the fight against cancer and to honor Julian, said Lowe, who is one of the organizers of Team Julian.

Proceeds from the event supports the Stamford-based Alliance for Cancer Gene Therapy, the nations only foundation dedicated exclusively to funding cancer gene therapy research.

To learn more about Swim Across America Fairfield County or make a donation, visit swimacrossamerica.org/fc.

dfierro@greenwichtime.com

Original post:
Greenwich swimmers take the plunge to fight cancer - Greenwich Time

Recommendation and review posted by Bethany Smith

Novartis has agreed to license Sangamo Therapeutics zinc finger protein transcription factors (ZFP-TFs) to develop gene regulation therapies for neurodevelopmental disorders that include autism spectrum disorder and intellectual disability, the companies said, through a collaboration that could generate more than $795 million for Sangamo.

Through Sangamos ZFP-TFs, the companies plan over three years to develop treatments addressing three target genes associated with neurodevelopmental disorders, by upregulating the expression of key genes that are inadequately expressed in individuals with certain neurodevelopmental disorders.

The goal is to create new gene regulation therapies that act at the genomic level, moving us beyond the symptom focused treatments of today and toward therapies that can address some of the most challenging neurodevelopmental disorders, Jay Bradner, president of the Novartis Institutes for BioMedical Research, said in a statement. This collaboration with Sangamo is part of our commitment to pioneering the next generation of neurodevelopmental treatments.

Sangamos ZFP-TF genome regulation technology, now delivered via adeno-associated viruses (AAVs), is designed to selectively repress or activate the expression of specific genes to achieve a desired therapeutic effect, at the DNA level.

While AAVs have many advantages that make them well-suited for gene therapy, Novartis says, they also have one disadvantage: They cant carry large genes. The collaboration is designed to enable the companies to target diseases caused by mutations in one copy of a large gene.

The gene for a ZFP-TF is small enough to fit inside an AAV, Ricardo Dolmetsch, head of neuroscience at the Novartis Institutes for BioMedical Research, explained in a post on the companys blog. We can use it to increase the production of a large gene in someone who still has one intact copy of the gene. This dramatically expands the range of diseases that we can potentially target with gene therapy because many diseases are caused by the loss of a single copy of a gene.

Each of Sangamos ZFP-TFs is engineered to bind to a target region of genomic DNA in a highly specific and selective manner. They can be designed to precisely modulate the expression of targeted genes to varying extents. After identifying its target, the ZFP-TF recruits other proteins that help switch genes on or off.

The zinc finger nuclease technology is remarkable, Macrae told GEN in January. Its one of the commonest transcripts in the body. Its natural and human, and its very, very adaptable. The individual units are modular, so one is always able to come up with a solution for any part of the genome.

For its part, Sangamo reasons that it can engineer zinc finger proteins to address virtually any genomic target.

We are building a broad pipeline of wholly owned and partnered programs with the goal to bring our genomic medicines to patients, stated Sangamo CEO Sandy Macrae. In the case of the central nervous system, there are potentially hundreds of neurological disease gene targets that may be addressable by our zinc finger platform.

For Sangamo, the collaboration with Novartis is the second signed this year that focuses on applying ZFP-TFs toward treating neurological disorders. In February, Sangamo launched a potentially more than $2.7 billion partnership to develop and commercialize Sangamo gene regulation therapies. The collaboration included ST-501 for tauopathies including Alzheimers disease, ST-502 for synucleinopathies including Parkinsons disease, a third treatment targeting an undisclosed neuromuscular disease target, and additional treatments for up to nine additional undisclosed neurological disease targets over five years.

In its latest partnership with Novartis, the Swiss pharma giant will have exclusive rights to ZFP-TFs targeting the genes, which are undisclosed, during the three-year collaboration period.

Novartis also has the option to license Sangamos AAVs. Sangamo has agreed to oversee specified research and associated manufacturing activities, all of which will be funded by Novartiswhile Novartis agreed to oversee additional research activities, investigational new drug-enabling studies, clinical development, related regulatory interactions, manufacturing, and global commercialization.

Novartis agreed to pay Sangamo a $75 million upfront license fee within 30 days, plus up to $720 million tied to achieving development and commercial milestonesconsisting of up to $420 million in development milestones and up to $300 million in commercial milestones.

Sangamo is also eligible to receive from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration.

Partnering Sangamos proprietary technology with Novartis deep experience in neuroscience drug development is a powerful combination which expands Sangamos pipeline and allows us to tackle challenging neurodevelopmental conditions, Macrae added.

More:
Novartis Taps Sangamo Zinc Finger Tech for Gene Regulation Therapies - Genetic Engineering & Biotechnology News

Recommendation and review posted by Bethany Smith

ASCO-Jonathan W. Friedberg has been appointed as the next editor-in-chief of theJournal of Clinical Oncology(JCO), the flagship journal of the American Society of Clinical Oncology (ASCO).JCOpublishes cutting-edge research on the diagnosis and treatment of patients with cancer and is one of the most highly cited oncology journals in the world. A hematologic oncologist for more than 20 years, Friedberg is currently director of the Wilmot Cancer Institute and Samuel Durand Professor of Medicine at the University of Rochester Medical Center in Rochester, New York. Friedbergs five-year term asJCOeditor-in-chief will begin in June 2021. He will succeed Stephen A. Cannistra, who will be completing his 10th year as the journals editor-in-chief.

Apic Bio Cambridge, Mass.-based Apic Bio formed a Scientific Advisory Board (SAB) which includes internationally recognized gene therapy experts. TheSAB will provide clinical and scientific expertise to help the company advance its pipeline and leverage its proprietary silence and replace THRIVE platform. The appointments to Apics Scientific Advisory Board include Robert H. Brown Jr., Leo P. and Theresa M. LaChance Chair in Medical Research, Professor of Neurology, Director of the Program in Neurotherapeutics, University of Massachusetts Medical School; R. Jude Samulski, president and chief scientific officer at AskBio; Barry Byrne, director of the Powell Gene Therapy Center at the University of Florida and Professor of Pediatrics and Molecular Genetics & Microbiology; Rob Kotin, adjunct professor at University of Massachusetts Medical School; Kevin Flanigan, Robert F. and Edgar T. Wolfe Foundation Endowed Chair in Neuromuscular Research and Director of the Center for Gene Therapy in The Abigail Wexner Research Institute at Nationwide Childrens Hospital, and professor of Pediatrics and Neurology at The Ohio State University College of Medicine; Mark Kay, Dennis Farrey Family Professor in Pediatrics and Professor of Genetics at Stanford University School of Medicine.

I-Mab Shanghai-based I-Mab named Ivan Yifei Zhuas its chief commercial officer effectiveAug. 10. In this role, Zhu will focus on building and developing I-Mab's commercialization infrastructure and strategies and preparing the company for upcoming product launches. Before joining I-Mab, he served as vice president and General Manager of the sales division of Qilu Pharmaceutical Group where he managed the company's sales and marketing team. Zhu also served as the CCO of BeiGene where he played an instrumental role in the expansion of BeiGene's commercialization team and the implementation of its commercialization strategies.

Caladrius Biosciences Michael H. Davidson was named to the board of directors of Caladrius Biosciences. Davidson is the founder and chief scientific officer of Corvidia Therapeutics, which recently announced its sale to Novo-Nordisk for $2.1 billion. Davidson also serves as clinical professor and director of the Lipid Clinic at the University of Chicago Pritzker School of Medicine.

Cidara Therapeutics-Cidara Therapeutics announced the formation of a scientific advisory board (SAB) and the appointment of four leading experts in viral and fungal infections and hematology. TheSABwill work closely with the Cidara management team to help guide the direction and design of the companys development programs with an emphasis on the continued development and expansion of the companys Cloudbreak Antiviral Conjugate (AVC) program.Cidara TherapeuticsSABincludes Frederick G. Hayden,Stuart S. Richardson Professor Emeritus of Clinical Virology atUniversity of Virginia School of Medicine; Professor Emeritus of Medicine at the University of Virginia; Michael G. Ison, professor, Divisions of Infectious Diseases and Organ Transplantation atNorthwestern University Feinberg School of Medicine; Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service at Northwestern University Comprehensive Transplant Center,Chicago; Johan A Maertens,professor of Internal Medicine and Hematology, Acute Leukemia and Transplantation Unit at University Hospitals Leuven;Department of Microbiology, Immunology and Transplantationat KULeuven, Leuven,Belgium; Kieren Marr, Professor of Medicine and Oncology Director, Transplant and Oncology Infectious Diseases Program and Vice-Chair for Innovation in Healthcare Implementation,Department of MedicineatJohns Hopkins University School of Medicine.

Alydia Health Following a $13.9 million Series C financing round, Alydia Health announced Rob Binney as its new chief executive officer. Binney joins the company from Intersect ENT where he served as chief commercial officer. Prior to Intersect ENT, Binney worked in leadership roles with both startups and large medical device companies, including Boston Scientific and AccessClosure, now part of Cardinal Health. Binney succeeds Anne Morrissey, who recently stepped down as the companys CEO. Colby Holtshouse, previously Alydias interim CEO and head of Marketing, will assume the role of chief operating officer. In association with the financing round, Zina Affas Besse, managing partner at Global Health Funds will join the companys board of directors.

Synlogic, Inc. Antoine Tony Awad was named chief operating officer of Synlogic. As COO, Awad will drive Synlogic's end to end development & manufacturing organization and supply chain as well as have broader corporate operations responsibilities, inclusive of laboratory operations, IT infrastructure, and the quality organization. Awad joined Synlogic in December 2018 as head of Technical Operations. Prior to joining Synlogic, he served as senior vice president of CMC and Operations at Abpro Therapeutics and L.E.A.F. Pharmaceuticals and served in roles of increasing responsibility at Ipsen Biosciences and Merrimack Pharmaceuticals. In addition to Awad, Synlogic also named Andrew March as head of Development Operations. Prior to joining Synlogic March served as Ra Pharmaceuticals' head of Clinical Development.

Engrail Therapeutics San Diego-based Engrail announced two key executive appointments. Kimberly Vanover has been named chief scientific officer, leading the building and advancement of the companys pipeline. Eve Taylor has been named vice president of clinical development, overseeing all facets of Engrails clinical development programs and operations. Stephen Cunningham, previously executive vice president, development and CSO, will assume the role of chief development officer. Vanover most recently served as senior vice president, early-stage clinical development and translational medicine at Intra-Cellular Therapies. Taylor most recently helped lead early-stage clinical development at Intra-Cellular Therapies. Previously, Taylor led clinical development activities at Cytori Therapeutics, Ceregene and ACADIA Pharmaceuticals. The company also expanded its board of directors to five members. Tony Ho was appointed to Engrails board of directors effective immediately. Ho served as CRISPR Therapeutics executive vice president, research and development since August 2017. Prior to joining CRISPR, Tony held a number of roles at AstraZeneca, most recently senior vice president and head of oncology integration and innovation.

CressetU.K.-based Cresset announced its SAB. The Cresset Scientific Advisory Board members are Stevan W Djuric, chairman of Discovery Chemistry and Technology Consulting LLC, USA;Richard Lewis of Novartis Pharma AG; Alexander Hillisch of Bayer; AstraZenecas Andreas Bender; Julien Michel of the University of Edinburgh; Paul Czodrowski of TU Dortmund University in Germany; and Kazuyoshi Ikeda of Keio University in Japan.

NeuBase Therapeutics William Mann was named chief operating officer of NeuBase Therapeutics. Mann will leverage his decades of experience in the biopharma industry to manage NeuBase operations and advance its strategic goals. Mann most recently served as the president and CEO of Helsinn Therapeutics. Before joining Helsinn, he held multiple positions at Sapphire Therapeutics, Inc.

Originally posted here:
Movers & Shakers, July 31 | BioSpace - BioSpace

Recommendation and review posted by Bethany Smith

Global Gene Therapy for Inherited Genetic Disorders market- Report defines the vital growth factors, opportunities and market segment of top players during the forecast period from 2019 to 2025. The report Gene Therapy for Inherited Genetic Disorders offers a complete market outlook and development rate during the past, present, and the forecast period, with concise study, Gene Therapy for Inherited Genetic Disorders market effectively defines the market value, volume, price trend, and development opportunities. The comprehensive, versatile and up-to-date information on Gene Therapy for Inherited Genetic Disorders market is provided in this report.

The latest research report on Gene Therapy for Inherited Genetic Disorders market encompasses a detailed compilation of this industry, and a creditable overview of its segmentation. In short, the study incorporates a generic overview of the Gene Therapy for Inherited Genetic Disorders market based on its current status and market size, in terms of volume and returns. The study also comprises a summary of important data considering the geographical terrain of the industry as well as the industry players that seem to have achieved a powerful status across the Gene Therapy for Inherited Genetic Disorders market.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2602855&source=atm

The key players covered in this studyBioMarin Pharmaceutical Inc.bluebird bio Inc.Novartis AGOrchard Therapeutics PlcSpark Therapeutics Inc.

Market segment by Type, the product can be split intoEye DisordersHematological DisordersCentral Nervous System DisordersMuscular DisordersOthersMarket segment by Application, split intoHospitalClinicResearch InstituteOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Gene Therapy for Inherited Genetic Disorders status, future forecast, growth opportunity, key market and key players.To present the Gene Therapy for Inherited Genetic Disorders development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Gene Therapy for Inherited Genetic Disorders are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2602855&source=atm

Complete Analysis of the Gene Therapy for Inherited Genetic Disorders Market:

Comprehensive assessable analysis of the industry is provided for the period of 2019-2025 to help investors to capitalize on the essential market opportunities.

The key findings and recommendations highlight vital progressive industry trends in the global Gene Therapy for Inherited Genetic Disorders market, thereby allowing players to improve effective long term policies

A complete analysis of the factors that drive market evolution is provided in the report.

To analyze opportunities in the market for stakeholders by categorizing the high-growth segments of the market

The numerous opportunities in the Gene Therapy for Inherited Genetic Disorders market are also given.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2602855&licType=S&source=atm

Furthermore, Global Gene Therapy for Inherited Genetic Disorders Market following points are involved along with a detailed study of each point:

Generation of this Global Gene Therapy for Inherited Genetic Disorders Industry is tested about applications, types, and regions with price analysis of players that are covered.

Revenue, sales are planned for this Gene Therapy for Inherited Genetic Disorders market, including with various essentials along yet another facet is assessed in this section for foremost regions.

In continuation using earnings, this section studies consumption, and global Gene Therapy for Inherited Genetic Disorders market. This area also sheds light on the variance between ingestion and distribution. Export and Gene Therapy for Inherited Genetic Disorders significance data are provided in this part.

In this section, key players have been studied depending on product portfolio, their Gene Therapy for Inherited Genetic Disorders market company profile, volume, price, price, and earnings.

Gene Therapy for Inherited Genetic Disorders market analysis aside from business, the information, and supply, contact information from manufacturers, consumers and providers can also be presented. Additionally, a feasibility study to asset and SWOT analysis for endeavors have been contained.

Continued here:
Gene Therapy for Inherited Genetic Disorders Market size in terms of volume and value 2019-2025 - Market Research Correspondent

Recommendation and review posted by Bethany Smith

MALVERN, Pa., July 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced the U.S. Food and Drug Administration (FDA) granted the third Orphan Drug Designation (ODD) for OCU400 in the treatment of RHO mutation-associated retinal degeneration. The RHO mutation is part of the Retinitis Pigmentosa (RP) group of rare, genetic disorders that involve a breakdown and loss of cells in the retina and can lead to visual impairment and blindness. This is one of the larger mutations within the RP class, representing about 12% of RP patients in the US.

A novel gene therapy product candidate, OCU400 has the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases. It consists of a functional copy of a nuclear hormone receptor (NHR) gene, NR2E3, delivered to target cells in the retina using an adeno-associated viral vector. As a potent modifier gene, expression of NR2E3 within the retina may help reset retinal homeostasis and potentially offer longer benefit, stabilizing cells and rescuing photoreceptor degeneration and vision loss.

Adding to ODDs for OCU400 for NR2E3 and CEP290 mutation-associated retinal degeneration, RHO gene mutation-associated retinal degeneration further supports Ocugens breakthrough modifier gene therapy platforms potential to treat multiple blindness diseases with a single product. RP is a group of heterogenic inherited retinal diseases associated with over 150 gene mutations, affecting over 1.5 million individuals worldwide. In addition, ~40% of RP patients cannot be genetically diagnosed, confounding the ability to develop personalized RP therapies. Traditional gene therapy or gene editing approaches may require more than 150 products to rescue these patients from vision loss. OCU400, a single product candidate, has potential to address broad-spectrum RP.

OCU400, comprising the nuclear hormone receptor geneNR2E3, has the potential to help modulate numerous biological pathways that function in maintaining the health of the retina. A recent preclinical study published in Nature Gene Therapy demonstrated the potency of NR2E3 to elicit broad-spectrum therapeutic benefits in early and intermediate stages of RP in five unique mouse models, said Dr. Mohamed Genead, acting Chief Medical Officer of Ocugen and Chair of Ocugens Retina Scientific Advisory Board. We believe OCU400 has the potential to address multiple genetic mutations associated with RP and, therefore, help a broader pool of patients, Dr. Genead continued.

Our third ODD for OCU400 from the FDA is an important step towards developing a broad-spectrum treatment for RP and getting a therapy faster to patients who are in desperate need of rescue, said Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen. Orphan designation for this indication supports the goal of our Modifier Gene Therapy Platform to treat a variety of inherited retinal diseases with a single gene therapy product. There are currently no approved treatments which slow or stop the progression of multiple forms of RP, which is why were excited to have a platform that can potentially address multiple mutations, including mutations in the Rhodopsin gene, with one therapy.

The FDA Office of Orphan Products Development grants orphan designation for novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. Orphan designation qualifies the sponsor of the drug for various development incentives of the Orphan Drug Act, including a seven-year period of U.S. marketing exclusivity, tax credits for clinical research costs, clinical research trial design assistance, the ability to apply for annual grant funding and waiver of Prescription Drug User Fee Act filing fees.

About OCU400OCU400 (AAV-hNR2E3) is a novel gene therapy product candidate with the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases. It consists of a functional copy of a nuclear hormone receptor gene, NR2E3, delivered to target cells in the retina using an adeno-associated viral vector. As a potent modifier gene, expression of NR2E3 within the retina may help reset retinal homeostasis, potentially stabilizing cells and rescuing photoreceptor degeneration and vision loss.

About Ocugen, Inc.Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. For more information, please visithttps://ocugen.com/

Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as predicts, believes, potential, proposed, continue, estimates, anticipates, expects, plans, intends, may, could, might, will, should or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the SEC), including the risk factors described in the section entitled Risk Factors in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Corporate Contact:Ocugen, Inc.Sanjay SubramanianChief Financial OfficerIR@Ocugen.com

Media Contact: LaVoieHealthScienceEmmie Twomblyetwombly@lavoiehealthscience.com+1 857-389-6042

Originally posted here:
Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative...

Recommendation and review posted by Bethany Smith

Hemophilia Gene Therapy Market 2020 Research Report provides Emerging Market trends, Market Segmentation, regional outlook and comprehensive analysis on different market segments. It also provides key analysis on the market status of the Hemophilia Gene Therapy manufacturers with best facts and figures, meaning, definition, SWOT analysis, expert opinions and the latest developments across the globe.This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

Final Report will add the analysis of the impact of COVID-19 on this industry.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT REQUEST SAMPLE

Short Description About Hemophilia Gene Therapy Market :

Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.

Get a Sample PDF of reporthttps://www.360researchreports.com/enquiry/request-sample/13851179

The research covers the current Hemophilia Gene Therapy market size of the market and its growth rates based on 5-year records with company outline ofKey players/manufacturers:

Scope of the Hemophilia Gene Therapy Market Report:

About 80% of them have hemophilia A, which affects the clotting factor VIII. The second most common form, hemophilia B, is due to a deficiency of the clotting factor IX. Several biotechs are racing to launch the first gene therapy for hemophilia. Currently, uniQure in the Netherlands and Spark Therapeutics in the US have the most advanced programs. Spark scored a victory in December when it presented Phase I/II for its candidate SPK-9001. The gene therapy was able to reduce annual bleeding episodes by 97%, as compared to its competitor uniQures candidate, AMT-060. However, uniQure has fought back. The company added a modification in its gene therapy that is known to increase clotting activity by 8- to 9- fold. This improved version has already been cleared to start a Phase III clinical trial in both Europe and the US.

Hemophilia B has traditionally been the main focus of biotechs, since most big pharma efforts were focused on the bigger hemophilia A market. In addition, applying gene therapy to hemophilia A is more challenging; The gene coding for the factor IX protein missing in hemophilia B is simply smaller than that for factor VIII missing in hemophilia A, and therefore easier to fit in the viral vectors used for gene delivery. US-based BioMarin is leading the development of a gene therapy. To overcome the size limit, the company has deleted a region from the factor VIII protein that is not necessary for clotting.

Hemophilia treatment is currently in the pre-clinical stage. And the multiple treatments that are underway might significantly improve the quality of life of patients with hemophilia, by getting rid of frequent infusions and hospital visits, and transitioning patients from severe to mild hemophilia.

The global Hemophilia Gene Therapy market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Hemophilia Gene Therapy.

Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.

This report studies the Hemophilia Gene Therapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Hemophilia Gene Therapy market by product type and applications/end industries.

Get a Sample Copy of the Hemophilia Gene Therapy Market Report 2020

Report further studies the market development status and future Hemophilia Gene Therapy Market trend across the world. Also, it splits Hemophilia Gene Therapy market Segmentation by Type and by Applications to fully and deeply research and reveal market profile and prospects.

Major Classifications are as follows:

Major Applications are as follows:

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Hemophilia Gene Therapy in these regions, from 2014 to 2024, covering

This Hemophilia Gene Therapy Market Research/Analysis Report Contains Answers to your following Questions

Inquire more and share questions if any before the purchase on this report at https://www.360researchreports.com/enquiry/pre-order-enquiry/13851179

Major Points from Table of Contents:

1. Market Overview1.1 Hemophilia Gene Therapy Introduction1.2 Market Analysis by Type1.3 Market Analysis by Applications1.4 Market Dynamics1.4.1 Market Opportunities1.4.2 Market Risk1.4.3 Market Driving Force

2.Manufacturers Profiles

2.4.1 Business Overview2.4.2 Hemophilia Gene Therapy Type and Applications2.4.2.1 Product A2.4.2.2 Product B

3.Global Hemophilia Gene Therapy Sales, Revenue, Market Share and Competition By Manufacturer (2019-2020)

3.1 Global Hemophilia Gene Therapy Sales and Market Share by Manufacturer (2019-2020)3.2 Global Hemophilia Gene Therapy Revenue and Market Share by Manufacturer (2019-2020)3.3 Market Concentration Rates3.3.1 Top 3 Hemophilia Gene Therapy Manufacturer Market Share in 20203.3.2 Top 6 Hemophilia Gene Therapy Manufacturer Market Share in 20203.4 Market Competition Trend

4.Global Hemophilia Gene Therapy Market Analysis by Regions

4.1 Global Hemophilia Gene Therapy Sales, Revenue and Market Share by Regions4.1.1 Global Hemophilia Gene Therapy Sales and Market Share by Regions (2014-2019)4.1.2 Global Hemophilia Gene Therapy Revenue and Market Share by Regions (2014-2019)4.2 North America Hemophilia Gene Therapy Sales and Growth Rate (2014-2019)4.3 Europe Hemophilia Gene Therapy Sales and Growth Rate (2014-2019)4.4 Asia-Pacific Hemophilia Gene Therapy Sales and Growth Rate (2014-2019)4.6 South America Hemophilia Gene Therapy Sales and Growth Rate (2014-2019)4.6 Middle East and Africa Hemophilia Gene Therapy Sales and Growth Rate (2014-2019)

5.Hemophilia Gene Therapy Market Forecast (2020-2024)5.1 Global Hemophilia Gene Therapy Sales, Revenue and Growth Rate (2020-2024)5.2 Hemophilia Gene Therapy Market Forecast by Regions (2020-2024)5.3 Hemophilia Gene Therapy Market Forecast by Type (2020-2024)5.3.1 Global Hemophilia Gene Therapy Sales Forecast by Type (2020-2024)5.3.2 Global Hemophilia Gene Therapy Market Share Forecast by Type (2020-2024)5.4 Hemophilia Gene Therapy Market Forecast by Application (2020-2024)5.4.1 Global Hemophilia Gene Therapy Sales Forecast by Application (2020-2024)5.4.2 Global Hemophilia Gene Therapy Market Share Forecast by Application (2020-2024)

6.Sales Channel, Distributors, Traders and Dealers6.1 Sales Channel6.1.1 Direct Marketing6.1.2 Indirect Marketing6.1.3 Marketing Channel Future Trend6.2 Distributors, Traders and Dealers

7.Research Findings and Conclusion

8.Appendix8.1 Methodology8.2 Data Source

Continued..

Purchase this report (Price3480 USD for a single-user license) https://www.360researchreports.com/purchase/13851179

About Us:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us:Name: Mr. Ajay MoreEmail: [emailprotected]Organization: 360 Research ReportsPhone: +44 20 3239 8187/ +14242530807

For More Related Reports Click Here :

Office Furniture Market Size 2020 is Worth 94200 Million USD By 2024 with a magnificent CAGR, Top Countries Data with Emerging Technologies and Demand, Defination, Industry Outlook

Global Glass Screen Protector Market Size 2020 is predicted to reach 1120 Million USD mark By 2024 with a magnificent CAGR and Covid 19 Impact Analysis with Top Countries Data, Defination, Industry Outlook

Global Luxury Packaging Market Size 2020 is predicted to reach 23600 Million USD mark By 2024 with a magnificent CAGR and Covid 19 Impact Analysis with Top Countries Data, Defination, Industry Outlook

Link:
Hemophilia Gene Therapy Market 2020 : Industry Outlook with Top Countries Data, Market Share, Growth Analysis, Opportunities and Forecast To 2024 -...

Recommendation and review posted by Bethany Smith

The Viral Vector and Plasmid DNA Manufacturing Market report 2020 covers all the significant developments which are recently being adopted across the global market. The prime objective of the Viral Vector and Plasmid DNA Manufacturing market report is to provides an in-depth analysis of all market dynamics including drivers and restraints, and trends, and opportunities. The Viral Vector and Plasmid DNA Manufacturing market report covers both the demand and supply aspects of the market. The report also highlighted the future trends in the Viral Vector and Plasmid DNA Manufacturing market that will impact the demand during the forecast period.

Scope of the Report:

As per the scope of this report, viral vectors and plasmid DNA are the products of gene therapy, which are used for the treatment of several diseases, such as Alzheimers disease, Parkinsons disease, and rheumatoid arthritis. Gene therapies and other therapies that require genetic modification include the introduction of therapeutic DNA/gene into a patients body or cell. This process is accomplished by the use of vectors. Over the past few decades, various viral and non-viral vectors have been developed and standardized for this purpose. Moreover, viral vectors and plasmid DNA are known to reduce the cost of treatment and help in decreasing repeated administrations of medications

Get a Sample Copy of the Report https://www.industryresearch.co/enquiry/request-sample/14244338

Market Overview:

Some of the Top Key Players of Viral Vector and Plasmid DNA Manufacturing Market Report Are:

Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14244338

Key Market Trends:

Plasmid DNA Segment is Expected to Register Robust Growth.

A plasmid DNA is a small DNA molecule within a cell that is different from the chromosomal DNA, which can replicate independently. Plasmid DNA is currently gaining increasing importance, due to the clinical research applications in gene therapy and genetic vaccination. The demand and therapeutic applications for plasmid DNA (pDNA) have rapidly grown and expanded. Plasmid DNA manufacturing is used for indirect and direct clinical applications. For the direct gene transfer into the human body, good manufacturing practice (GMP)-grade plasmid DNA is being required. The plasmid DNA manufacturing is invariably outsourced to the specialized manufacturers using the in-house platform processes.

North America Dominates the Market in Terms of Revenue Generated

Currently, North America is witnessing a rapid growth in the market studied, followed by Europe. The United States has been a major destination for all the recent advancements in the field of medicine. Increasing investments in gene therapy products in the United States have led to the growth of the market studied in recent years. In the United States, regulatory encouragement and patient advocacy have pushed rare disease clinical research to the center stage. The significant incentives offer through Orphan Drugs Act (United States) and the Orphan Medicinal Products Regulations (European Union) have encouraged pharmaceutical and biotechnology companies to consider the development of rare disease medicines as a potentially profitable endeavour.

The Report Covers:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/14244338

Detailed TOC of Viral Vector and Plasmid DNA Manufacturing Market Report 2020-2024:

1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases4.2.2 Increasing Number of Clinical Studies and Availability of Funding for Gene Therapy Development4.2.3 Potential Applications in Novel Drug Delivery Approaches4.3 Market Restraints4.3.1 High Cost of Gene Therapies4.3.2 Challenges in Viral Vector Manufacturing Capacity4.4 Porters Five Force Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION5.1 By Product Type5.1.1 Plasmid DNA5.1.2 Viral Vector5.1.3 Non-viral Vector5.2 By Application5.2.1 Cancer5.2.2 Genetic Disorder5.2.3 Infectious Disease5.2.4 Other Diseases5.3 Geography5.3.1 North America5.3.1.1 US5.3.1.2 Canada5.3.1.3 Mexico5.3.2 Europe5.3.2.1 Germany5.3.2.2 UK5.3.2.3 France5.3.2.4 Italy5.3.2.5 Spain5.3.2.6 Rest of Europe5.3.3 Asia-Pacific5.3.3.1 China5.3.3.2 Japan5.3.3.3 India5.3.3.4 Australia5.3.3.5 South Korea5.3.3.6 Rest of Asia-Pacific5.3.4 Middle East & Africa5.3.4.1 GCC5.3.4.2 South Africa5.3.4.3 Rest of Middle East & Africa5.3.5 South America5.3.5.1 Brazil5.3.5.2 Argentina5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Brammer Bio6.1.2 Cobra Biologics6.1.3 Cell and Gene Therapy Catapult6.1.4 FinVector Vision Therapies6.1.5 Fujifilm Diosynth Biotechnologies6.1.6 MassBiologics6.1.7 SIRION Biotech6.1.8 Merck KGaA Inc.6.1.9 Thermo Fisher Scientific6.1.10 Uniqure NV

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Metal-Clad Switchgear Market Expected Growth Analysis with Revenue, Future Trends and Technology, Top Coverage of Key Companies with Size and Share Forecast by 2020-2026

Single Monaural Bluetooth Headset Market 2020 2025 Industry Forecast Analysis by Global Opportunities, Development Size, Organization Share, Market Components, and Regional Outlook

Sport and Recreation Aircraft Market Growth Rate by Share 2020-2026 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry

Solid Tyre Market Size, Share | Growth Analysis by Revenue, Future Demand Status, Price Analysis by Types and Applications till 2020-2026

Anti-Snoring Market Size Analysis with Growth Prospects and Share 2020 | Global Industry Overview by Size, Top Manufacturers, Supply Demand, Growth Statistics, Overview, Forecast to 2024

Ambulatory Surgery and Emergency Center Services Market Size, Share | Growth Analysis by Revenue, Future Demand Status, Price Analysis by Types and Applications till 2020-2026

Read more here:
Viral Vector and Plasmid DNA Manufacturing Market Report 2020: Global Industry Size Analysis by Value Chain, SWOT Analysis, Drivers and Opportunities...

Recommendation and review posted by Bethany Smith

The Gene Therapy Market market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

It incorporates Gene Therapy Market market evolution study, involving the current scenario, growth rate (CAGR), and SWOT analysis. Important the study on Gene Therapy Market market takes a closer look at the top market performers and monitors the strategies that have enabled them to occupy a strong foothold in the market. Apart from this, the research brings to light real-time data about opportunities that will completely transform the trajectory of the business environment in the coming years to 2025. Some of the key players in the global Gene Therapy Market market is Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical, Advantagene.

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ https://brandessenceresearch.com/requestSample/PostId/417

Gene Therapy Market Market: Competitive Landscape:

The competitive landscape further includes details about different players and their position on a global and a local level is also explained in detail in this compiled study. These insights were prepared through mapping business strategies and products that offer high revenue generation capacities. An overview of the Gene Therapy Market market Comprehensive analysis of the market Analyses of recent developments in the market Events in the market scenario of the past few years Emerging market segments and regional Gene Therapy Market markets Segmentations up to the second and/or third level Historical, current, and estimated market size in terms of value and volume Competitive analysis, with company overview, products, revenue, and strategies. An impartial assessment of the market Strategic recommendations to help companies increase their Gene Therapy Market market presence.

The Key Manufacturers covered in this Report:- Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical, Advantagene.

By Therapy Type:-SomaticGermlineBy Vector Type:-

non-viral Vectorsviral vectorsBy Application:-

Cancer DiseasesMonogenic DiseasesInfectious DiseasesCardiovascular Diseases Others

The key regions covered in the Gene Therapy Market market report are:

North America (U.S., Canada, Mexico)

South America (Cuba, Brazil, Argentina, and many others.)

Europe (Germany, U.K., France, Italy, Russia, Spain, etc.)

Asia (China, India, Russia, and many other Asian nations.)

Pacific region (Indonesia, Japan, and many other Pacific nations.)

Middle East & Africa (Saudi Arabia, South Africa, and many others.)

Request Customization of the Report: https://brandessenceresearch.com/requestSample/PostId/417

Table of Contents

Report Overview: It includes major players of the global Gene Therapy Market Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends: This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Gene Therapy Market Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Gene Therapy Market Market are discussed.

Market Share by Manufacturers: Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type: This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application: Besides an overview of the global Gene Therapy Market Market by application, it gives a study on the consumption in the global Gene Therapy Market Market by application.

Production by Region: Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Gene Therapy Market Market are profiled in this section. The analysts have provided information about their recent developments in the global Gene Therapy Market Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Gene Therapy Market Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Gene Therapy Market Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Gene Therapy Market Market.

Key Findings: This section gives a quick look at important findings of the research study.

Get access to full summary @ https://brandessenceresearch.com/healthcare/gene-therapy-market-global

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://www.marketwatch.com/press-release/global-ipaas-market-analysis-2020-2025-covering-recent-trend-and-future-growth-feasibility-regional-outlook-and-future-forecast-2020-05-27

https://www.marketwatch.com/press-release/magnesium-oxide-market-global-industry-analysis-and-opportunity-assessment-2020-2025-2020-05-27

https://www.marketwatch.com/press-release/cloud-telephony-service-market-2020-by-advanced-technologies-growth-opportunities-key-players-revenue-emerging-trends-and-business-strategy-till-2025-2020-05-27

https://www.marketwatch.com/press-release/global-phosphate-fertilizers-market-2020-share-trends-segmentation-and-forecast-to-2025-2020-06-15

https://www.marketwatch.com/press-release/carbonated-beverages-market-2020-industry-research-share-trend-global-industry-size-price-future-analysis-regional-outlook-to-2025-2020-06-15

Go here to see the original:
Global Gene Therapy Market Market Analysis by SWOT, Investment, Future Growth and Major Key Players 2020 to 2025 - Research Newspaper

Recommendation and review posted by Bethany Smith